[User] <|image|>Express the image as Markdown code.

[Assistant]
<md> | S.N. | Genes | Types | Functions | References |
 | --- | --- | --- | --- | --- |
 | 1 | KNOX | Transcription factor | Regulation of meristem identity in plants (monocots and dicot); Activation/repression of GA-synthesis genes | [95, 96] |
 | 2 | CLAVATA1(CLV1) | Receptor-like kinase | Maintenance of an equilibrium between cell enlargement and organ development; Regulation of apical/floral meristem determinacy | [76, 97] |
 | 3 | CLAVATA 3 (CLV3) | Peptide | Binding with the receptor-like kinase CLV1 as its ligand; Restricts WUS expression | [65, 76] |
 | 4 | AUXIN-BINDING PROTEIN 1 (ABP1) | Auxin binding protein | ABP1- TMK1 complex formation for auxin perception; Maintenance of asymmetric growth at floral primordial region | [75, 99] |
 | 5 | RHO OF PLANTS 6 (ROP6) | Plasma membrane associated small GTPase | Regulation of cellular processes; Maintenance of asymmetric growth under the influence of auxin | [75] |
 | 6 | SEPALLATA 3 (SEP3) | MADS-domain transcription factor | Interaction with floral genes AG and AP3; Regulation of floral organ formation | [98] |
 | 7 | ROP-INTERACTIVE CRIB MOTIF-CONTAINING PROTEIN 1 (RIC1) | CRIB-containing ROP effector | Regulator of ROP6 gene; Maintenance of asymmetric growth under the influence of auxin | [99] |
 | 8 | APETALA 1 (AP1) | MADS-domain transcription factor | Chromatin remodelling; Regulation of flower initiation | [74, 98] |
 | 9 | WUSCHEL (WUS) | Homeodomain transcription factor | Stem cell activity in meristematic regions; Regulation offloral meristem determinacy | [65] |
 | 10 | LEAFY (LFY) | Transcription factor | Regulation of floral meristem identity; Activator of AG, AP3 and AP1 genes | [73, 74] | </md>


[User] <|image|>Transcribe the table into Markdown format.

[Assistant]
<md> | <ROWSPAN=3>  | Control | <ROWSPAN=3> % | Case | <ROWSPAN=3> % | <ROWSPAN=3> P |
 | N = 938 | N = 962 |
 | N | N |
 | --- | --- | --- | --- | --- | --- |
 | Gender |  |  |  |  | 0.60 |
 | Women | 343 | 36.6 | 363 | 37.7 |  |
 | Men | 595 | 63.4 | 599 | 62.3 |  |
 | Hypoglycemic drugs (Yes) | 49 | 5.2 | 130 | 13.5 | <.0001 |
 | Lipid lowering drugs (yes) | 44 | 4.7 | 99 | 10.3 | <.0001 |
 | Current smoker | 132 | 14.1 | 173 | 18.0 | 0.020 |
 | Current drinker | 539 | 57.5 | 545 | 56.7 | 0.72 |
 | Regular sports habit | 669 | 71.3 | 636 | 66.1 | 0.014 |
 |  | Mean | SD | Mean | SD |  |
 | Age, yrs | 54.5 | 10.6 | 55.1 | 10.6 | 0.22 |
 | Body mass index, kg/m2 | 22.7 | 2.3 | 27.1 | 3.0 | <.0001 |
 | Waist circumference, cm | 79.2 | 6.4 | 94.2 | 7.1 | <.0001 |
 | Systolic blood pressure, mmHg | 122.7 | 14.8 | 133.2 | 14.9 | <.0001 |
 | Diastolic blood pressure, mmHg | 72.9 | 9.8 | 79.2 | 10.3 | <.0001 |
 | Total cholesterol, mg/dL | 203.0 | 36.5 | 206.8 | 36.7 | 0.025 |
 | Triglycerides, mg/dL | 115.0 | 74.3 | 177.6 | 103.8 | <.0001 |
 | HDL cholesterol, mg/dL | 43.2 | 9.8 | 38.5 | 7.0 | <.0001 |
 | LDL cholesterol, mg/dL | 116.4 | 31.6 | 124.7 | 32.7 | <.0001 |
 | Fasting glucose, mg/dL | 93.3 | 22.7 | 105.2 | 28.1 | <.0001 |
 | Postprandial glucose, mg/dL | 120.1 | 52.3 | 129.8 | 59.2 | 0.0002 |
 | Uric acid, mg/dL | 6.1 | 1.5 | 6.6 | 1.6 | <.0001 | </md>


[User]
<|image|>Continue parse the table with markdown style: <md> |  | Topic selection | Tools development | Pilot testing |
 | --- | --- | --- | --- |
 | Professional society |  |  |  |
 | Dutch Order of Medical Specialists (OMS) | + | + | + |
 | Dutch College of General Practitioners (NHG) | + | + | + |
 | Royal Dutch Society for Physical Therapy (KNGF) | + | + | + |
 | Dutch Association of Nurses and Care Providers (V&VN) | + | + | - |
 | Dutch Association of Youth Health Care Doctors (AJN) | + | + | - |
 | Dutch Urological Association (NVU) | - | - | + |
 | Research institute |  |  |  |
 | Netherlands Organisation for Applied Scientific Research (TNO) | + | + | + |
 | Netherlands institute for health services research (NIVEL) | +

[Assistant]
| + | - |
 | institute for Medical Technology Assessment (iMTA) | + | + | - |
 | Quality improvement organization |  |  |  |
 | Dutch Institute for Healthcare Improvement (CBO) | + | + | + |
 | Dutch Council for Quality of Healthcare | + | + | - |
 | Knowledge institute |  |  |  |
 | Trimbos Institute | + | + | + |
 | Dutch Youth Health Centre (NCJ) | + | + | + |
 | Netherlands Youth Institute (NJi) | + | + | + |
 | Medical Centre |  |  |  |
 | Academic Medical Center (AMC) | + | + | - |
 | Onze Lieve Vrouwe Gasthuis (OLVG) | + | + | - |
 | Radboud University Nijmegen Medical Centre (RUNMC) | + | + | + |
 | University Medical Center Groningen (UMCG) | + | + | - |
 | Leiden University Medical Center (LUMC) | + | + | + |
 | University Medical Center Utrecht | + | + | + |
 | Educational organizations |  |  |  |
 | Maastricht University | + | + | + |
 | Utrecht University | + | + | + |
 | Disease specific organization |  |  |  |
 | Comprehensive Cancer Centre The Netherlands (IKNL) | + | + | + |
 | Dutch Lung Alliance (LAN) | - | - | + |
 | Other |  |  |  |
 | PROVA | + | + | + |
 | Federation of Patients and Consumers Organisations in the Netherlands (NPCF) | + | + | - |
 | Dutch Burns Foundation | - | - | + | </md>


[User]
<|image|>Continue parse the illustration with markdown style: <md> | <ROWSPAN=2> Personal barrier | <COLSPAN=2> Survivor | <COLSPAN=2> Comparison | <ROWSPAN=2> P value |
 | % | M (SD) | % | M (SD) |
 | --- | --- | --- | --- | --- | --- |
 | Lack of energy | 19.2 | 1.4 (1.1) | 17.0 | 1.5 (1.2) | NS |
 | Lack of self-discipline | 19.2 | 1.3 (1.2) | 25.5 | 1.5 (1.2) | NS |
 | Lack of time | 17.0 | 1.5 (1.1) | 46.8 | 2.4 (1.1) |

[Assistant]
0.007 |
 | Lack of skills | 10.6 | 1.0 (1.1) | 8.5 | 0.9 (1.0) | NS |
 | No one to do physical activity with | 10.4 | 1.1 (1.2) | 12.8 | 1.3 (1.2) | NS |
 | The weather is bad | 8.5 | 1.2 (0.9) | 4.3 | 1.3 (1.0) | NS |
 | Self-conscious about my looks when exercising | 6.4 | 0.8 (0.9) | 8.5 | 0.9 (1.1) | NS |
 | Lack of knowledge about how to be physically active | 4.2 | 0.6 (0.8) | 6.4 | 0.7 (0.8) | NS |
 | I am too overweight | 2.1 | 0.3 (0.8) | 0 | 0.2 (0.5) | NS |
 | Physical activity is boring | 2.1 | 0.8 (0.9) | 2.1 | 0.8 (1.0) | NS |
 | Friends tease me during exercise or sports | 2.1 | 0.3 (0.6) | 0 | 0.4 (0.6) | NS |
 | Someone told me not to exercise | 2.1 | 0.1 (0.3) | 0 | 0.1 (0.4) | NS | </md>


[User]
<|image|>Parse the following content of the figure in markdown code: <md> | Total N=641 | Low | Intermediate | High |
 | --- | ---

[Assistant]
| --- | --- |
 | AHA/ACC/ACEP | 57 (9%) | 290 (45%) | 294 (45%) |
 | EP | 257 (40%) | 265 (41%) | 119 (19%) | </md>


[User] <|image|>Express the figure as Markdown code.

[Assistant]
<md> | Abbreviation | Domain | Range |
 | --- | --- | --- |
 | C | Basic care (support needs) | 0–4 |
 | R | Risk (cognitive or behavioural needs) | 0–4 |
 | N | Skilled nursing needs | 0–4 |
 | M | Medical needs | 0–4 |
 | <COLSPAN=3> Therapy needs |
 | TD | Required number of different therapy disciplines | 0–4 |
 | TI | Therapy intensity | 0–4 |
 | E | Equipment needs | 0–2 | </md>


[User] <|image|>Translate the table into Markdown format.

[Assistant]
<md> | Strap condition | Vertical breast displacement (cm) |
 | --- | --- |
 | Vertical orientation |  |
 | Standard | 3.3 ± 1.0 |
 | Wide | 3.2 ± 1.1 |
 | Gel | 3.3 ± 1.1 |
 | Cross-back orientation |  |
 | Standard | 3.1 ± 1.1 |
 | Wide | 3.1 ± 1.0 |
 | Gel | 3.2 ± 1.1 | </md>


[User]
<|image|>Parse the following content of the illustration in markdown code: <md> |  | Difference, compliance score mean (CI) | P value |
 | --- | --- | --- |
 | The individual therapy, N = 40 | 0.400 (−0.174–0.974) | >0.05 |
 | The system-oriented therapy, N

[Assistant] = 30 | 1.103 (0.434–1.733) | <0.05 | </md>


[User] <|image|>Transform the image into Markdown format.

[Assistant]
<md> | Groups | Number of brain cysts (means ± SD) |
 | --- | --- |
 | Blank control | 3366.67 ± 115.47 |
 | PBS | 3463.33 ± 109.70 |
 | pVAX I | 3150.00 ± 129.41 |
 | pVAX-GRA16 | 1866.67 ± 152.75∗∗∗ | </md>


[User] <|image|>Transform the picture into Markdown format.

[Assistant]
<md> | Outcomes | <COLSPAN=2> Transportation (Compliant, n = 24) | <COLSPAN=2> Dog (n = 35) |
 |  | Pre-IV | Post-IV | Pre-IV | Post-IV |
 | --- | --- | --- | --- | --- |
 | Knowledge | 5.79 (1.32) (5.24, 6.35) | 6.33 (1.24) (5.81, 6.86) | 5.97 (1.38) (5.49, 6.45) | 6.50 (1.29) (6.05, 6.95) |
 | Simulated Behavior | 6.65 (3.56) (5.14, 8.15) | 6.87 (3.06) (5.54, 8.19) | 6.80 (2.68) (5.88, 7.72) | 6.50 (2.94) (5.48, 7.52) | </md>


[User]
<|image|>What are the following photo content in markdown style: <md> |  | With a friend | Duration |
 | --- | --- | --- |
 | Interest/Enjoyment | .203* | .306** |
 | Social | .191* | .201* |
 | Appearance | .104

[Assistant]
| -.241** |
 | Competence | -.005 | .084 |
 | Fitness | -.022 | .036 | </md>


[User] <|image|>Convert the table into Markdown format.

[Assistant]
<md> | Semester | Topic | ECTS |
 | --- | --- | --- |
 | 1 | Introduction to EBP in health care | 15 |
 | 2 | EBP-Implementation I (clinical practice) | 15 |
 | 3 | Philosophy of science, methodologies and methods | 15 |
 | 4 | EBP-Implementation II (organization) | 15 |
 | 5 | Developing a research project and in-depth research methods | 15 |
 | 6–8 | Master’s thesis | 45 | </md>


[User] <|image|>Convert the illustration to Markdown syntax.

[Assistant]
<md> | Uptake Index | 0 μg/ml SP-D | 1 μg/ml SP-D | 10 μg/ml SP-D |
 | --- | --- | --- | --- |
 | MDM | 685.4 ± 193.2 | 511.3 ± 212.7 | 815.5 ± 289.9 |
 | EC | 9.9 ± 2.5 | 55.8 ± 32.8 | 64.1 ± 26.4 |
 | MDDC | 1982 ± 1346 | 1018 ± 455.9 | 570.6 ± 232.2 | </md>


[User]
<|image|>Continue parse the illustration with markdown style: <md> | Class | Gene | Chromosomal location | Protein | Mass (kDa) | Sequence length (AA) |
 | --- | --- | --- | --- | --- | --- |
 | Class I |  |  |  |  |  |
 | IA | PIK3CA | 3q26.3 | p110-α | 124.28 | 1068 |
 |  | PIK3CB | 3q22.3 | p110-β | 122.76 | 1070 |
 |  | PIK3CD | 1p36.2 | p110-δ | 119.48 | 1044 |
 |  | PIK3R1 | 5q13.1 | p85-α | 83.60 | 724 |
 |  | PIK3R2 | 19p13.1 | p85-β | 81.55 | 728 |
 |  | PIK3R3 | 1p34.1 | p55-γ | 54.45 | 461 |
 | IB |  |  |  |  |

[Assistant]
|
 |  | PIK3CG | 7q22.3 | π110-γ | 126.45 | 1102 |
 |  | PIK3R5 | 17p13.1 | p101 | 97.35 | 880 |
 |  | PIK3R6 | 17p13.1 | p84/p87PIKAP | 84.26 | 754 |
 | Class II |  |  |  |  |  |
 |  | PIK3C2A | 11p15.1 | PIK-C2α | 190.68 | 1686 |
 |  | PIK3C2B | 1q32.1 | PIK-C2β | 184.77 | 1634 |
 |  | PIK3C2G | 12p12.3 | PIK-C2γ | 165.72 | 1445 |
 | Class III |  |  |  |  |  |
 |  | PIK3C3 | 18q12.3 | hVps34 | 101.55 | 887 |
 |  | PIK3R4 | 3q22.1 | p150 | 153.10 | 1358 | </md>


[User] <|image|>Express the figure as Markdown code.

[Assistant]
<md> | Variables | Unstandardized coefficienta | Standardized coefficient (β)a | t value | P value |
 | --- | --- | --- | --- | --- |
 | <COLSPAN=5> Operation type |
 | Robot assisted | REF | – | – | – |
 | Open | −0.017 | −0.325 | −7.259 | < 0.001 |
 | Laparoscopic | −0.008 | −0.146 | −3.730 | < 0.001 |
 | Blood loss (L) | −0.023 | −0.205 | −5.438 | < 0.001 |
 | <COLSPAN=5> Gleason score |
 | ≤ 6 | REF | – | – | – |
 | 7 | −0.003 | −0.061 | − 1.668 | 0.096 |
 | ≥ 8 | −0.009 | −0.152 | −4.115 | < 0.001 |
 | White blood count (× 109/L) | 0.002 | 0.089 | 2.775 | 0.006 |
 | Preoperative PSA | 8.222E-6 | 0.007 | 0.208 | 0.835 |
 | Dysuresia | −0.002 | −0.027 | −0.826 | 0.409 |
 | Platelet count (× 109/L) | 2.816E-5 | 0.053 | 1.550 | 0.122 |
 | Serum calcium (mmol/L) | −0.012 | − 0.058 | −1.797 | 0.073 |
 | Blood glucose (mmol/L) | 0.001 | 0.043 | 1.352 | 0.177 | </md>


[User] <|image|>Convert the diagram to Markdown syntax.

[Assistant]
<md> | Pt. no. | Grade 1–2 toxicity | Grade 3-4 |
 | --- | --- | --- |
 | 1 | Mucositis, Fatigue | / |
 | 2 | Fatigue | / |
 | 3 | Loss of appetite, Xerostomia, Diarrhea, Fatigue, Erythema, Conjunctivitis | / |
 | 4 | Nausea | / |
 | 5 | Xerostomie, Parotitis, Headache, Fatigue | / |
 | 6 | Loss of appetite, Fatigue, Nausea, Dysgeusia | / |
 | 7 | Loss of appetite, Nausea, Headache, Neck pain | / |
 | 8 | Loss of appetite, Nausea, Fatigue | / |
 | 9 | Xerostomia | / | </md>


[User]
<|image|>Parse the following content of the diagram in markdown code: <md> |  | Cases (n = 144) | Controls (n = 280) | p-value |
 | --- | --- | --- | --- |
 | Preoperative characteristics |  |  |  |
 | Gender (male) | 93 (64.6 %) | 181 (64.6 %) | 1.00 |
 | Age (years) | 70 (43–89) | 70 (42–89) | 0.81 |
 | Parsonnet score | 18.3 (0–49.0) | 16.5 (0–52.5) | 0.28 |
 | Renal failurea | 22 (15.3 %) | 29 (10.4 %) | 0.16 |
 | Severe peripheral vascular disease | 13 (9 %) | 17 (6.1 %) | 0.32 |
 | Cardiogenic shockb | 5 (3.5 %) | 1 (0.4 %) | 0.02 |
 | Preoperative intra-aortic balloon pump | 16 (11.1 %) | 10 (3.6 %) | 0.004 |
 | Chronic obstructive pulmonary diseasec | 10 (6.9 %) | 48 (17.1 %) | 0.004 |
 | Diabetesd | 38 (26.4 %) | 103 (36.8 %) | 0.04 |
 | Postoperative characteristics |  |  |  |
 | Peak lactate (mmol/L) | 4.6 (3.0–18.0)

[Assistant]
| 2.1 (0.8–2.9) | <0.0001 |
 | Peak serum creatinine level (mmol/L) | 127 (66–840) | 100 (39–1013) | <0.0001 |
 | Intra-aortic balloon pump | 29 (20.1 %) | 14 (5 %) | <0.0001 |
 | Computed tomography chest /abdomen | 4 (2.8 %) | 0 | 0.01 |
 | Return to operating room | 22 (15.3 %) | 5 (1.8 %) | <0.0001 |
 | Cardiogenic shock | 9 (6.3 %) | 2 (0.7 %) | 0.002 |
 | Post-operative cardiac hemorrhage | 9 (6.3 %) | 4 (1.4 %) | 0.01 |
 | Acute kidney injury (AKIN 1) | 68 (50.4 %) | 73 (26.8 %) | <0.0001 |
 | Ischemic bowel | 1 (0.7 %) | 0 | 0.34 |
 | Length of ICU admission (days) | 3 (1–96) | 1 (1–29) | <0.0001 |
 | ICU readmission | 12 (8.3 %) | 13 (4.7 %) | 0.13 |
 | Mechanical ventilation (days) | 0.89 (0.14–75.5) | 0.50 (0.09–11.9) | <0.0001 |
 | Mortality | 15 (10.4 %) | 4 (1.4 %) | <0.0001 | </md>


[User] <|image|>Transcribe the photo into Markdown format.

[Assistant]
<md> |  | Estimate | SE | z | P |
 | --- | --- | --- | --- | --- |
 | Intercept | −2.829 | 0.447 | −6.333 | <0.0001 |
 | Sex M | 0.954 | 0.598 | 1.594 | 0.111 |
 | Age Juvenile | 0.878 | 0.305 | 2.877 | 0.004 |
 | Age Adult | −0.073 | 0.316 | −0.232 | 0.817 |
 | Band Size | 0.061 | 0.035 | 1.778 | 0.075 |
 | Density | 0.093 | 0.025 | 3.649 | 0.0003 |
 | Sex M × Age Juvenile | −0.226 | 0.430 | −0.526 | 0.599 |
 | Sex M × Age Adult | −1.866 | 0.585 | −3.193 | 0.0014 |
 | Sex M × Band Size | −0.120 | 0.059 | −2.040 | 0.041 | </md>


[User] <|image|>Convert the image into Markdown format.

[Assistant]
<md> | Measure | Description | Range |
 | --- | --- | --- |
 | <COLSPAN=3> Similarity scores for term pairs |
 | Resnik [6] | Information content of the most informative common ancestor of two terms | ≥ 0 |
 | Lin [5] | Normalized Resnik similarity score by assessing how close two terms are to their most informative common ancestor | [0, 1) |
 | RS [4] | Weighted Lin similarity score by using the probability of annotations of the most informative common ancestor | [0,1) |
 | Jiang [7] | Based on the difference between two terms and their most informative common ancestor in information content | (0,1] |
 | <COLSPAN=3> Similarity scores for protein pairs based on pairwise similarity scores between term groups |
 | AVG [2] | The average of the similarity scores for all pairs of terms between two groups of protein annotations | Same with those for the corresponding similarity scores for term pairs |
 | BMA [3] | The score of the best-matching pairs between two groups of protein annotations |  |
 | <COLSPAN=3> Similarity scores for protein pairs based on groupwise similarity scores between term groups |
 | TO [9] | The number of terms shared by the annotations for two proteins | ≥ 1 |
 | NTO [9] | Dividing TO by the minimum of the annotation lengths of two proteins | (0,1] |
 | Dice [12] | Dividing TO by the average of annotation lengths of two proteins | (0,1] |
 | Kappa [11] | A chance-corrected measure of co-occurrence between two groups of protein annotations | [0, 1] |
 | GIC [8] | Jaccard index weighted by the information content of each GO term | [0, 1] |
 | VSM [10] | Cosine similarity weighted by the information content of each GO term | [0, 1] | </md>


[User]
<|image|>Parse the table content behind with markdown code: <md> |  | <COLSPAN=2> Men (n = 101) | <COLSPAN=2> Women (n = 78) |  |
 |  | Mean | (SD) | Mean | (SD) | p-value |
 | --- | --- | --- | --- | --- | --- |
 | Age | 44.2 | (13.0) | 46.6 | (13.3) | 0.22 |
 | Physical activity (1–4) | 2.0 | (0.8) | 1.9 | (0.5) | 0.19

[Assistant]
|
 | BMI | 26.9 | (3.9) | 26.3 | (6.1) | 0.39 |
 | Chest pain intensity (0–100 mm)a | 61 | (23) | 65 | (25) | 0.27 |
 | Confrontive coping (0–52) | 31.1 | (7.4) | 30.8 | (5.6) | 0.81 |
 | Emotive coping (0–36) | 17.0 | (4.5) | 18.4 | (3.6) | 0.03 |
 | Palliative coping (0–56) | 27.2 | (5.0) | 28.1 | (4,9) | 0.21 |
 | Negative life events (0–30) | 5.8 | (4.2) | 6.3 | (4.5) | 0.45 |
 | Stress at home (0–5) | 1.8 | (1.5) | 1.9 | (1.6) | 0.68 |
 | Sleep problems (0–20) | 7.9 | (5.2) | 8.8 | (5.0) | 0.27 |
 | Mental strain at work (2–10) | 6.1 | (2.3) | 6.0 | (2.1) | 0.82 | </md>


[User]
<|image|>Parse the following content of the diagram in markdown code: <md> | Patient | Age (years) | Died on day | Resuscitation during surgery | Blood-loss (l) | Complications | Organ failure | Infectious complication |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | 1 | 79 | 2 | - | 7.0 |  | Respiratory and renal | - |
 | 2 | 80 | 3 | - | 9.5 | Sigmoid necrosis, ischemic lower legs | Respiratory, cardiovascular and renal | - |
 | 3 | 74 | 4 | - | 2.0 |  | Respiratory, cardiovascular and renal | - |
 | 4 | 79 | 12 | - | 2.5 | Sigmoid

[Assistant]
necrosis | Respiratory, hepatic, cardiovascular and renal | Enterococci in blood culture |
 | 5 | 79 | 21 | - | 3.0 | Wound infection | Respiratory, cardiovascular and renal | Proteus mirabilis in wound and blood |
 | 6 | 76 | 30 | + | 25.0 | Sigmoid necrosis | Respiratory, cardiovascular and renal | - | </md>


[User]
<|image|>What are the following figure content in markdown style: <md> | mRNA | Sequence of primer | Product (bp) | Accession numbers |
 | --- | --- | --- | --- |
 | EP-1 | 5' -GCT GTA CGC CTC GCA TCG TGG-3'5' -GTG TTT CGA GCA TCC CAT GTA TCT-3' | 404 | NCBI:D16338 |
 | EP-2 | 5' -GAA CGC TAC CTC TCC ATC GG-3'5' -TGA TGG TCA TAA TGG-3' | 415 | NCBI:D50589 |
 |

[Assistant]
COX-1EP-3 | 5' -GTTTGGTCTG GCGTCTTAGA AC-3'5' -CTTGGAACAG GACCTTCTGA GT-3'5' -TTTGCCTCCGCCTTCGCCTG-3'5' -AGCAGCAGATAAACC-3' | 399,359 | U03388 NCBI:D14869 |
 | COX-2EP-4 | 5' -AATGAGTACC GCAAA-3'5' -ATCTAGTCTG GAGCGGGAGG-3'5' -TGCTCATCTGCTCCATTCCGC-3'5' -ATGCGAACCTGGAAG-5' | 420,407 | NM011198NCBI:D28860 |
 | Col ICOX-1 | 5' -TGGTGACAAG GGTGAGACAG-3'5' -TGAGGCAGGA AGCTGAAGTC-3'5' -GTTTGGTCTG GCGTCTTAGA AC-3'5' -CTTGGAACAG GACCTTCTGA GT-3' | 329,399 | Z78279NCBI:U03388 |
 | Col IICOX-2 | 5' -CTCCAGGTGT GAAGGGTGAG-3'5' -GAACCTTGAG CACCTTCAGG-3'5' -AATGAGTACC GCAAA-3'5' -ATCTAGTCTG GAGCGGGAGG-3' | 261,420 | NM012929NCBI:NM011198 |
 | Col XI | 5' -TGCCTCTTGT CAGTGCTAAC C-3'5' -GCGTGCCGTT CTTATACAGG-3'5' -TGGTGACAAG GGTGAGACAG-3'5' -TGAGGCAGGA AGCTGAAGTC-3' | 248329 | AJ131848NCBI:Z78279 |
 | β-actinCol II | 5' -CATCACCATT GGCAATGAGC G-3'5' -CTAGAAGCAT TTGCGGTCGG AC-3'5' -CTCCAGGTGT GAAGGGTGAG-3'5' -GAACCTTGAG CACCTTCAGG-3' | 403,261 | NM031144NCBI:NM012929 |
 | Col X | 5' -TGCCTCTTGT CAGTGCTAAC C-3'5' -GCGTGCCGTT CTTATACAGG-3' | 248 | NCBI:AJ131848 |
 | β-actin | 5' -CATCACCATT GGCAATGAGC G-3'5' -CTAGAAGCAT TTGCGGTCGG AC-3' | 403 | NCBI:NM031144 | </md>


[User] <|image|>Encode the table in Markdown syntax.

[Assistant]
<md> |  | Small NHs* N = 15 | Large NHs** N = 17 | P value |
 | --- | --- | --- | --- |
 | Specialized medical manager (%) | 6 (40.0%) | 7 (41.2%) | .615 |
 | Physician availability per day |  |  |  |
 | Up to 8 hours | 10 (66.7%) | 5 (29.4%) | <ROWSPAN=3> .102 |
 | 9-12 hours | 2 (13.3%) | 6 (35.3%) |
 | 13 and more hours | 3 (20.0%) | 6 (35.3%) |
 | Registered nurse availability per shift (%) |  |  |  |
 | Morning | 4 (26.7%) | 2 (11.8%) | <ROWSPAN=3> .550 |
 | Morning and afternoon | 4 (26.7%) | 6 (35.3%) |
 | Morning, afternoon and night | 7 (46.7%) | 9 (52.9%) |
 | Referral form (%) |  |  |  |
 | Direct | 10 (66.7%) | 15 (88.2%) | <ROWSPAN=2> .149 |
 | Indirect | 5 (33.3%) | 2 (11.8%) |
 | Average referral rate per 100 financed beds (SD)*** | 69.1 (SD = 54.0) | 63.7 (SD = 28.1) | .722 |
 | Average annual mortality rate per 100 financed beds (SD) | 35.3 (SD = 19.2) | 31.3 (SD = 15.8) | .525 |
 | Average length of stay in days in general hospitals (SD) | 7.2 (SD = 3.3) | 6.4 (SD = 1.5) | .400 | </md>


[User] <|image|>Express the illustration as Markdown code.

[Assistant]
<md> |  | BEM | FEM | iFDM | aFDM |
 | --- | --- | --- | --- | --- |
 | Position of computational points | Surface | Volume | Volume | Volume |
 | Free choice of computational points | Yes | Yes | No | No |
 | System matrix | Full | Sparse | Sparse | Sparse |
 | Solvers | Direct/iterative | Iterative | Iterative | Iterative |
 | Number of compartments | Small | Large | Large | Large |
 | Requires tessellation | Yes | Yes | No | No |
 | Handles anisotropy | No | Yes | No | Yes | </md>


[User] <|image|>Render the figure in Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Variables used | <COLSPAN=3> Coded levels |
 | −1 | 0 | +1 |
 | --- | --- | --- | --- |
 | Xanthan gum (mg) | 40 | 50 | 60 |
 | Locust bean gum (mg) | 60 | 70 | 80 | </md>


[User]
<|image|>Continue parse the figure with markdown style: <md> | Groups | SHi | SHf | % Hardness Loss |
 | --- | --- | --- | --- |
 | GP5 – 5% palm oil | 329.92 (±35.81) | 253.90 (±45.15) | 23.24 (±8.436)a

[Assistant]
|
 | GP100 – pure palm oil | 337.58 (±28.41) | 310.80 (±34.58) | 7.89 (±7.5)b |
 | GC5 – 5% coconut oil | 334.16 (±26.88) | 250.92 (±37.49) | 24.65 (±11.50)a |
 | GC100 – pure coconut oil | 336.24 (±30.50) | 240.26 (±48.45) | 28.47 (±13.37)a |
 | GSa5 – 5% safflower oil | 341.19 (±31.87) | 241.90 (±37.23) | 28.74 (±11.53)a |
 | GSa100 – pure safflower oil | 337.85 (±29.91) | 248.89 (±43.01) | 26.56 (±9.51)a |
 | GSu5 – 5% sunflower oil | 335.76 (±26.05) | 259.23 (±50.07) | 22.92 (±12.94)a |
 | GSu100 – pure sunflower oil | 338.51 (±27.63) | 265.02 (±55.67) | 21.78 (±14.83)ab |
 | GO5 – 5% olive oil | 337.27(±32.29) | 252.81 (±57.71) | 25.35 (±12.76)a |
 | GO100 – pure olive oil | 337.36 (±29.49) | 249.86 (±46.95) | 25.91(±12.51)a |
 | CON− – deionized water (negative control) | 335.45 (±29.71) | 240.90 (±38.02) | 28.09 (±9.95)a |
 | CON+ – fluoride mouthrinse (positive control) | 337.19 (±28.92) | 256.44 (±22.04) | 23.74 (±6.15)a | </md>


[User]
<|image|>Continue parse the table with markdown style: <md> | miRNAs | Accession Number | Primers [5′→3′] |
 | --- | --- | --- |
 | hsa-miR-1180-3p | MIMAT0005825 | GCTCGCGTGGGTGTGTAAAAA |
 | hsa-miR-1180-5p | MIMAT0026735 | CTGCTGGACCCACCCGAAAA |
 | hsa-miR-1247-3p | MIMAT0022721 | ACCCCGGGAACGTCGAGAAA |
 | hsa-miR-149-3p | MIMAT0004609 | AGGAGGGAGGGAGGGACAAA |
 | hsa-miR-192-5p | MIMAT0000222 | GGGCTCTGACCTATGAATTGAA |
 | hsa-miR-194-5p | MIMAT0000460 | CGCGTAACAGCAACTCCAAAAA |

[Assistant]
| hsa-miR-21-3p | MIMAT0004494 | GGCAACACCAGTCGATGAAAAA |
 | hsa-miR-27a-5p | MIMAT0004501 | CAGGGCTTAGCTGCTTGTGAA |
 | hsa-miR-29a-5p | MIMAT0004503 | GACTGATTTCTTTTGGTGTTCAG |
 | hsa-miR-324-5p | MIMAT0000761 | CCCCTAGGGCATTGGTGTAAA |
 | hsa-miR-4286 | MI0015894 | ACCCCACTCCTGGTACCAAAA |
 | hsa-miR-449c-5p | MIMAT0010251 | CAGTGTATTGCTAGCGGCTGT |
 | hsa-miR-454-3p | MIMAT0003885 | GGTGCAATATTGCTTATAGGGA |
 | hsa-miR-4710 | MI0017344 | GTGGGGTGAGGGCAGGTAAA |
 | hsa-miR-499a-5p | MIMAT0002870 | CGGCTGTTAAGACTTGCAGAAA |
 | hsa-miR-500a-3p | MIMAT0002871 | GCAATGCACCTGGGCAAGAAA |
 | hsa-miR-500a-5p | MIMAT0004773 | ATCCTTGCTACCTGGGTGAGA |
 | hsa-miR-500b-5p | MIMAT0016925 | AATCCTTGCTACCTGGGTAAAA |
 | hsa-miR-548v | MIMAT0015020 | CAGTTACTTTTGCACCAGCCTA |
 | hsa-miR-660-3p | MIMAT0022711 | CTGTGTGCATGGATTACAGGAA |
 | hsa-miR-9-5p | MIMAT0000441 | GGCTCTTTGGTTATCTAGCTGA |
 | <ROWSPAN=2> U6 |  | GCTTCGGCAGCACATATACTAA |
 |  | GCTTCACGAATTTGCGTGTCAT | </md>


[User] <|image|>Convert the image into Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Date | <COLSPAN=2> Working time | <ROWSPAN=2> TWA-S [ppbv] |
 | Beginning | End |
 | --- | --- | --- | --- |
 | October 27th 2009 | 02:00 pm | 10:00 pm | 45.1 |
 | October 27th 2009 | 10:00 pm | 06:00 am | 22.1 |
 | October 28th 2009 | 06:00 am | 02:00 pm | 8.3 |
 | October 28th 2009 | 02:00 pm | 10:00 pm | 23.9 |
 | October 28th 2009 | 10:00 pm | 06:00 am | 18.7 |
 | October 29th 2009 | 06:00 am | 02:00 pm | 17.1 | </md>


[User] <|image|>Transcribe the picture into Markdown format.

[Assistant]
<md> | <ROWSPAN=2>  | Irritable group | Stable group | <ROWSPAN=2> P |
 | n = 32 | n = 32 |
 | --- | --- | --- | --- |
 | Histrionic personality trait, mean ± SD | 9.5 ± 3.1 | 6.9 ± 2.9 | 0.001 |
 | Extravert, n (%) | 17 (53.1) | 12 (37.5) | 0.209 |
 | SCL-90-R, mean ± SD |  |  |  |
 | Somatization | 48.6 ± 9.9 | 47.2 ± 8.7 | 0.549 |
 | Obsession-compulsion | 46.0 ± 10.2 | 46.1 ± 11.1 | 0.879 |
 | Interpersonal sensitivity | 47.1 ± 8.6 | 46.5 ± 10.2 | 0.822 |
 | Depression | 46.5 ± 7.9 | 46.7 ± 9.2 | 0.954 |
 | Anxiety | 52.8 ± 8.6 | 46.1 ± 9.6 | 0.004 |
 | Hostility | 45.1 ± 6.9 | 45.8 ± 8.1 | 0.727 |
 | Phobic anxiety | 48.4 ± 9.8 | 46.9 ± 8.3 | 0.513 |
 | Paranoid ideation | 46.0 ± 8.3 | 43.7 ± 7.1 | 0.232 |
 | Psychoticism | 47.7 ± 7.0 | 47.4 ± 7.5 | 0.877 | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> | Case No | Pathology | CK | EMA | NSE | Syn | CgA | CD56 | S-100 | TTF-1 |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | 1 | SCC | ++ | +++ | +++ | +++ | ++ | +++ | - | +++ |
 | 2 | SCC | +++ | ++ | + | ++ | - | + | - | - |
 | 3 | SCC | ++ | +++ | ++ | +++ | + | +++ | - | ++ |
 | 4 | SCC | +++ | ++ | ++ | ++ | ++ | ++ | ++ | +++ |
 | 5 | SCC | ++ | +++ | - | + | - | +++ |  | - |
 | 6 | SCC | ++ | ++ | + | +++ | ++ | ++ | - | +++ |
 | 7 | SCC | +++ | ++ | + | ++ | + | +++ | + | ++ |
 | 8 | SCC | +++ | ++ | +++ | ++ | - | +++ | - | ++ |
 | 9 | SCC | - | - | +++ | +++ | ++ | +++ | ++ | +++ |
 |  | SqCC | +++ | ++ | - | - | - | - | - | - |
 | 10 | SCC | - | + | + | +++ | +++ | - | - | ++ |
 | 11 | SCC | - | - | - | ++ | - | ++ | - | - |
 | 12 | SCC | - | - | - | ++ | - | - | - | + |
 | 13 | SCC | - | - | ++ | +++ | ++ | +++ | - | - |
 | 14 | SCC | ++ | - | + | +++ | ++ | ++ | - | +++ |
 | 15 | SCC | + | ++ | - | ++ | ++ | +++ | - | ++ |
 | 16 | SCC | - | - | - | ++ | - | - | - | ++ |
 | 17 | SCC | ++ | +++ | ++ | +++ | + | +++ | + | - |
 | 18 | SCC | - | ++ | - | - | ++ | - | - | +++ |
 | 19 | SCC | ++ | ++ | - | ++ | - |

[Assistant]
+++ | - | - |
 | 20 | SCC | - | - | + | +++ | - | ++ | - | ++ |
 | 21 | SCC | - | - | - | +++ | +++ | - | - | ++ |
 |  | SqCC | +++ | - | - | - | - | - | - | - |
 | <COLSPAN=2> Total positive cases (%) | 12(57.1) | 13(61.9) | 13(61.9) | 20(95.2) | 13(61.9) | 16(76.2) | 4(19.0) | 15(71.4) | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> | Elements | Fe | Si | Cu | Mn | Mg | Zn | Al |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | Composition (wt.%) | 0.15 | 0.10 | 0.05

[Assistant] | 0.02 | 0.001 | 0.01 | Bal. | </md>


[User] <|image|>Encode the diagram in Markdown syntax.

[Assistant]
<md> | Study name (reference) | No patients | BB used | Description | Main findings | Additional findings and comments |
 | --- | --- | --- | --- | --- | --- |
 | MDC (Waagstein et al., 1993) | 383 | Metoprolol | HF secondary to Dilated Cardiomyopathy (EF <40%) | 34% decrease in mortality or need for transplantation | No significant difference in mortality alone |
 | MERIT-HF (Hjalmarson et al., 2000) | 3991 | Metoprolol succinate | Mild-moderate HF (EF <40%) NYHA II-IV | <34% decrease in all cause mortality | <39% decrease in cardiac death and non-fatal MI |
 | CIBIS (CIBIS Investigators and Committees, 1994) | 641 | Bisoprolol | Moderate HF (EF <40%) NYHA III-IV | No significant difference in mortality | Significant improvement of functional status of the patients |
 | CIBIS II (CIBIS-II Investigators, 1999) | 2647 | Bisoprolol | Moderate HF (EF <35%) NYHA III-IV | 32% decrease risk of mortality and hospitalization for HF | Greatest effects in patients with ischaemic HF and NYHA III at baseline |
 | CIBIS III (Willenheimer et al., 2005) | 1010 | Bisoprolol (vs. enalapril) | Mild moderate HF (EF <35%) NYHA II-III | Non-inferiority of bisoprolol vs enalapril in reducing mortality as first treatment in ITT | Non-inferiority of bisoprolol was not proven in per-protocol analysis |
 | US Carvedilol study (Packer et al., 1996) | 1094 | Carvedilol | Mild moderate HF NYHA II-IV | 65% mortality reduction | 38% reduction in death or hospitalization for cardiovascular reasons |
 | COPERNICUS (Packer et al., 2002) | 2289 | Carvedilol | Severe HF (EF <25%) NYHA III-IV | 35% in risk of death | 27% decrease death or hospitalization for a cardiovascular reason |
 | CAPRICORN (The CAPRICORN Investigators, 2001) | 1959 | Carvedilol | Patients with recent MI and left ventricular dysfunction (EF <40%) | 23% reduction in mortality | No significant difference in primary endpoint (all-cause mortality or hospitalization for cardiovascular problems) |
 | COMET (Poole-Wilson et al., 2003) | 3029 | Carvedilol vs. Metoprolol tartrate | Mild moderate HF (EF <35%) NYHA II-IV | 17% decrease in carvedilol- vs. metoprolol- arm | Concerns about metoprolol formulation |
 | BEST (BEST Investigators, 2001) | 2708 | Bucindolol | Mild moderate HF (EF <35%) NYHA III-IV | No significant overall survival benefit | Reduction in mortality in patients homozygous for Arg389 (subsequent pharmacogenetic analysis) |
 | SENIORS (Flather et al., 2005) | 2128 | Nebivolol | Mild moderate HF (EF <35% in last 6-months) Age >70yrs | 14% reduction mortality and hospitalizations | Significant increase of LVEF and decrease in end-systolic volume | </md>


[User]
<|image|>Parse the following content of the illustration in markdown code: <md> | Author group | Year of publication | Dental status | Rehabilitation procedures | Remarks |
 | --- | --- | --- | --- | --- |
 | Frydrych et al. (n = 82) [9] | 2011 | No information | No information | Average (median) date of last dental visit: 66.76 months (18 months) before radiotherapy |
 | <ROWSPAN=4> Guggenheimer et al. (n = 947) [10] | <ROWSPAN=4> 1994 | Edentulous: 59% | <ROWSPAN=4> No information | <ROWSPAN=4>  |
 | Partially edentulous: 9% |
 | Poor

[Assistant]
dentition with no replacement: 14% |
 | Intact dentition: 18% |
 | <ROWSPAN=3> Maier et al. (n = 100) [11] | <ROWSPAN=3> 1993 | <ROWSPAN=2> Tumour vs. control patients: Tartar > 3 mm: 40.91 vs. 21.98% | <ROWSPAN=3> No information | Tumour vs. control patients |
 | Never tooth brushing 44.9 vs. 23.5% |
 | Decayed teeth >50% : 27.2 vs. 3.9% | Dental visit more than once a year: 6% vs. 43.5% |
 | <ROWSPAN=3> Lockhart et al. (n = 131) [12] | <ROWSPAN=3> 1994 | Alveolar bone loss: 66% | Needing dental care: 97% | Noncompliant with routine dental care: 76% |
 | Clinical caries: 71% | <ROWSPAN=2> Did not seek the indicated treatment: 81% | <ROWSPAN=2> Noncompliant with routine oral hygiene: 65% |
 | Failing restorations: 91% |
 | <ROWSPAN=3> Jham et al. (n = 207) [7] | <ROWSPAN=3> 2008 | Periodontal disease: 41% | <ROWSPAN=3> No information | <ROWSPAN=3>  |
 | Residual root: 21.2% |
 | Caries 12% |
 |  |  | Unerupted tooth: 5.8% |  |  | </md>


[User] <|image|>Convert the picture into Markdown format.

[Assistant]
<md> | Factors |  | Median survival | P-value |
 |  |  | (months) |  |
 | --- | --- | --- | --- |
 | Age (yrs) | ≤60 | 9.8 ± 4.9 | 0.585 |
 |  | >60 | 13.6 ± 2.1 |  |
 | Gender | Male | 12.9 ± 1.9 | 0.293 |
 |  | Female | 11.6 ± 1.0 |  |
 | ECOG | 1 | 15.9 ± 4.0 | 0.070 |
 |  | 2 | 9.8 ± 3.1 |  |
 | Etiology | Viral | 11.3 ± 1.4 | 0.344 |
 |  | Non-viral | 13.6 ± 2.2 |  |
 | Child-Pugh | A | 13.0 ± 1.5 | 0.309 |
 | Classification | B | 6.4 ± 0.8 |  |
 | JIS score | 2 | 13.0 ± 1.4 | 0.235 |
 |  | 3 | 5.8 ± 0.3 |  |
 | Pretreatment | ≤ 20 | 15.9 ± 1.6 | 0.161 |
 | AFP (ng/ml) | > 20 | 10.9 ± 1.0 |  |
 | Type of HCC | Nodular | 11.3 ± 0.7 | 0.853 |
 |  | Diffuse infiltrative | 13.6 ± 4.4 |  |
 | Multiplicity | Solitary | 11.3 ± 1.3 | 0.534 |
 |  | Multiple | 13.9 ± 2.1 |  |
 | Location of thrombi | PV branch | 16.6 ± 5.9 | 0.036 |
 |  | Main portal trunk | 9.8 ± 4.2 |  |
 | BED (Gy10) | < 75 | 13.0 ± 1.4 | 0.901 |
 |  | ≥ 75 | 9.8 ± 4.7 |  |
 | PVTT response | CR + PR | 13.9 ± 1.1 | 0.142 |
 |  | SD + PD | 6.9 ± 5.1 |  | </md>


[User] <|image|>Render the diagram in Markdown format.

[Assistant]
<md> | Type | Level of Care | Services offered |
 | --- | --- | --- |
 | Specialist | Multi-disciplinary care | Type A hospital with specialized patient population |
 | Type A | Multi-disciplinary care | Tertiary referral hospital with access to sub-speciality care and advanced investigational facilities |
 | Type B | Large Urban hospital | Secondary care in basic specialties: general surgery, paediatrics, internal medicine, obstetrics and gynaecology. |
 | Type C | Basic district hospital | Inpatient and outpatient care with basic radiographic and laboratory services | </md>


[User]
<|image|>Continue parse the picture with markdown style: <md> | ACIC Component | Correlationcoefficient | p-value | Correlationcoefficientadjusted forclustering effect | p-value |
 | --- | --- | --- | --- | --- |
 | Total ACIC score | .44 | <.0001 | .38 | <.0001 |
 | Community linkages | .28 | <.0001 | .26 | <.0001 |
 | Self-management support | .40 | <.0001 | .35 | <.0001 |

[Assistant]
| Decision support | .39 | <.0001 | .33 | <.0001 |
 | Delivery system design | .45 | <.0001 | .39 | <.0001 |
 | Clinical information system | .38 | <.0001 | .25 | <.001 |
 | Health system support | .43 | <.0001 | .38 | <.001 |
 | Integration of elements | .45 | <.0001 | .42 | <.0001 | </md>


[User]
<|image|>Parse the following content of the photo in markdown code: <md> | Item | Yes | No |
 | --- | --- | --- |
 | Family members | 6 | 94 |
 | Close friends | 0 | 100 |
 | Acquaintances | 72 | 28 |
 | Strangers |

[Assistant]
73 | 27 |
 | Authority figures (e.g., professors) | 63 | 37 |
 | Classmates | 50 | 50 | </md>


[User] <|image|>Render the figure in Markdown format.

[Assistant]
<md> | Number of LNM | Under the ICBN | Above the ICBN | Patients |
 | --- | --- | --- | --- |
 | 1 | + | - | 16 |
 | 2 | + | - | 31 |
 | <ROWSPAN=2> 3 | + | - | 9 |
 | + | + | 2 |
 | 4 | + | + | 1 | </md>


[User]
<|image|>Parse the following content of the picture in markdown code: <md> |  | Asthman(%) | Diabetesn(%) | Rheumatoid Arthritisn(%) | p-value* |
 | --- | --- | --- | --- |

[Assistant]
--- |
 | <20,000 | 12 (13) | 2 (6) | 0 (0) | 0.03** |
 | 20,000-50,000 | 52 (63) | 37 (49) | 56 (58) | 0.23 |
 | >50,000 | 77(60) | 89 (72) | 53 (64) | 0.12 | </md>


[User]
<|image|>Continue parse the figure with markdown style: <md> | Order of rank | Kernel edge length (cm) | No of iterations (updates) | Cutoff frequency (cm−1) | pvalue |
 | --- | --- | --- | --- | --- |
 | 1 | 2.3 | 6 (96) | 0.7 | 2.8 × 10−14 |
 | 2 | 1.7 | 8 (128) | 0.7 | 3.1 × 10−14 |
 | 3 | 2.3 | 8 (128) | 0.6 | 3.1 × 10−14 |
 | 4 | 3.0 | 8 (128) | 0.7 | 3.1 × 10−14 |
 | 5 | 3.0 | 6 (96) | 0.7 | 3.3 × 10−14 |
 | 6 | 3.0 | 6 (96) | Unfiltered | 3.3 × 10−14

[Assistant]
|
 | 7 | 3.0 | 4 (64) | 0.7 | 3.5 × 10−14 |
 | 8 | 1.7 | 10 (160) | 0.7 | 3.8 × 10−14 |
 | 9 | 2.3 | 8 (128) | 0.7 | 4.4 × 10−14 |
 | 10 | 1.7 | 6 (96) | 0.7 | 4.7 × 10−14 | </md>


[User]
<|image|>What are the following illustration content in markdown style: <md> | mVSD size | Number of patients | Rate of follow up recommendation (%) |
 | --- | --- | --- |
 | Isolated small | 509 (85%) | 32 |
 | Isolated small-to-moderate | 12 (2%) | 42 |
 | Isolated moderate | 19 (3%) | 84

[Assistant]
|
 | Multiple small | 60 (10%) | 58 | </md>


[User] <|image|>Transcribe the illustration into Markdown format.

[Assistant]
<md> |  | univariate |  |  |  | <COLSPAN=2> multivariate |
 | --- | --- | --- | --- | --- | --- | --- |
 |  |  |  | <COLSPAN=2> initial model | <COLSPAN=2> final model |
 |  | HR | p | HR | p | HR | p |
 | age>65 years | 2.99 | <0.0001 | 3.53 | <0.0001 | 3.43 | <0.0001 |
 | male sex | 1.86 | 0.0018 | 1.84 | 0.0030 | 1.80 | 0.0038 |
 | ALC>14 × 109/L | 1.67 | 0.0062 | 1.34 | 0.17 | - |  |
 | β2M>1 × ULN | 1.43 | <0.0001 | 1.51 | 0.06 | 1.59 | 0.029 |
 | LNR ≥3 | 3.06 | <0.0001 | 1.20 | 0.59 | - |  |
 | Binet stage |  | <0.0001 |  |  |  |  |
 | A | ref |  | ref |  | ref |  |
 | B | 3.20 |  | 2.19 | 0.0352 | 2.77 | <0.0001 |
 | C | 4.95 |  | 2.86 | 0.0028 | 3.68 | <0.0001 |
 | Rai stage |  | <0.0001 |  |  |  |  |
 | 0 | ref |  | ND |  |  |  |
 | I-II | 1.66 |  | ND |  |  |  |
 | III-IV | 5.08 |  | ND |  |  |  |
 | CD38>30% | 1.73 | 0.0038 | 1.03 | 0.88 | - |  |
 | ZAP-70>20% | 1.53 | 0.0204 | 1.04 | 0.83 | - |  |
 | Unmutated IGHV | 2.46 | <0.0001 | 2.04 | 0.0008 | 2.04 | 0.0003 |
 | del17p | 3.44 | <0.0001 | 2.14 | 0.0015 | 2.06 | 0.0022 |
 | del11q | 1.39 | 0.248 | ND |  |  |  |
 | Year of diagnosis |  | 0.0130 | <COLSPAN=2> (in model as strata)* | <COLSPAN=2> (in model as strata)* |
 | <2001 | ref |  |  |  |  |  |
 | 2001-2005 | 1.46 |  |  |  |  |  |
 | >2005 | 2.34 |  |  |  |  |  |
 | Therapy |  | 0.106 | ND |  |  |  |
 | Chemotherapy | ref |  |  |  |  |  |
 | Immunochemotherapy | 0.6 |  |  |  |  |  | </md>


[User] <|image|>Translate the picture into Markdown format.

[Assistant]
<md> | Analytes | Regression Equation | r2 | Test range(μg/mL) | LOQ (μg/mL) | LOD (μg/mL) |
 | --- | --- | --- | --- | --- | --- |
 | Hypohorine | y = 0.0102 x + 0.0107 | 0.9994 | 1.0-100.0 | 1.0 | 0.4 |
 | THSG | y = 0.0061 x + 0.1012 | 0.9988 | 10.9-1090.0 | 5.4 | 2.0 |
 | Epicatechin | y = 0.0241 x + 0.0327 | 0.9996 | 1.0-100.0 | 1.0 | 0.3 |
 | Proanthocyanidin B2 | y = 0.0279 x + 0.0389 | 0.9988 | 1.0-100.0 | 1.0 | 0.4 |
 | Proanthocyanidin B1 | y = 0.0403 x + 0.0540 | 0.9988 | 1.0-103.0 | 1.0 | 0.3 |
 | Catechin | y = 0.0365 x + 0.0592 | 0.9978 | 1.0-100.0 | 1.0 | 0.4 |
 | Gallic acid | y = 0.0662 x + 0.0929 | 0.9982 | 1.3-130.0 | 1.3 | 0.5 | </md>


[User] <|image|>Transcribe the image into Markdown format.

[Assistant]
<md> |  | N (%) |
 | --- | --- |
 | Age (years) |  |
 | 7 | 16 (31.4) |
 | 8 | 5 (9.8) |
 | 9 | 9 (17.6) |
 | 10 | 6 (11.8) |
 | 11 | 8 (15.7) |
 | 12 | 6 (11.8) |
 | 13 | 1 (2.0) |
 | Sex |  |
 | Male | 26 (51.0) |
 | Female | 25 (49.0) |
 | Race |  |
 | White (Non-Hispanic) | 39 (76.5) |
 | Hispanic | 1 (2.0) |
 | >1 Race Listed | 11 (21.6) |
 | Parent Highest Education |  |
 | High School or less | 3 (5.9) |
 | College Degree (AS, BS, BA) | 18 (35.3) |
 | Graduate Degree | 28 (54.9) | </md>


[User]
<|image|>What are the following figure content in markdown style: <md> | Pathogen species detected | Positive cattle (%) |
 | --- | --- |
 | One pathogen |  |
 | B. bovis | 6 (15.8) |
 | T.

[Assistant]
velifera | 1 (2.6) |
 | A. marginale | 3 (7.9) |
 | Two pathogens |  |
 | B.bigemina + T. parva | 1 (2.6) |
 | B.bigemina + T. taurotragi | 1 (2.6) |
 | B.bovis + B. bigemina | 1 (2.6) |
 | T. parva + T. velifera | 2 (5.3) |
 | T. taurotragi + T.velifera | 1 (2.6) |
 | T. parva + T. taurotragi | 1 (2.6) |
 | Three pathogens |  |
 | B. bovis + T. parva + T. mutans | 2 (5.3) |
 | B. bigemina + T. parva + T. velifera | 2 (5.3) |
 | A. marginale + T. parva + T. velifera | 2 (5.3) |
 | A. marginale + T. parva + T. mutans | 1 (2.6) |
 | T. parva + T. taurotragi + T. velifera | 1 (2.6) |
 | Total | 25 (65.8) | </md>


[User]
<|image|>Parse the diagram content behind with markdown code: <md> | <ROWSPAN=2> Factors | <COLSPAN=2> Univariable analysis | <COLSPAN=2> Multivariable analysisa |
 | OR (95 % CI) | p-value | OR (95 % CI) | p-value |
 | --- | --- | --- | --- | --- |
 | Male gender | 4.57 (0.82–25.41) | 0.083 | <ROWSPAN=7>  | <ROWSPAN=7>  |
 | Age (years) | 1.00 (0.94–1.07) | 0.904 |
 | Loss to follow-up period (months) | 1.03 (0.97–1.08) | 0.371 |
 | Glaucoma family history (n) | 3.31 (0.54–20.41) | 0.196 |
 | Past medical history (n) |  |  |
 | Diabetes mellitus | 3.44 (0.31–38.48) | 0.315 |
 | Hypertension | 1.64 (0.17–15.98) | 0.671 |
 | Baseline IOP (mm Hg) | 1.74 (1.19–2.56)b | 0.005 | <ROWSPAN=3> 1.63 (1.03–2.57)b | <ROWSPAN=3> 0.037 |
 | MD (dB) | 0.90 (0.46–1.76) | 0.750 |
 | PSD (dB) | 3.08 (0.40–23.53) | 0.279 |
 | Average RNFL thickness (μm) | 0.83 (0.75–0.92) | 0.001b | <ROWSPAN=4> 0.84 (0.75–0.95)b |

[Assistant]
<ROWSPAN=4> 0.004 |
 | VCDR | 3.14 (0.00–47.13) | 0.851 |
 | Central corneal thickness (μm) | 1.00 (0.97–1.02)b | 0.766 |
 | Refractive error (SE, diopter) | 0.70 (0.49–1.00)b | 0.053 | </md>


[User] <|image|>Express the table as Markdown code.

[Assistant]
<md> | Species | Breeding colony | Geographical coordinates | # nestlings | # pairs | # nests |
 | --- | --- | --- | --- | --- | --- |
 | Wood Stork, Mycteria americana | Fazenda Ipiranga (PAN) | 16 ̊25' S, 56 ̊ 36' W | 13 | 5 | 6 |
 | Wood Stork, Mycteria americana | Porto da Fazenda (PAN) | 16 ̊27' S, 56 ̊ 07' W | 25 | 15 | 12 |
 | Wood Stork, Mycteria americana | Tucum (PAN) | 16 ̊26' S, 56 ̊ 03' W | 28 | 14 | 14 |
 | Wood Stork, Mycteria americana | Presidente (PAN) | 16°43' S, 57° 50' W | 18 | 9 | 9 |
 | Wood Stork, Mycteria americana | Macacoari (AP) | 00°27' N, 50° 40' W | 109 | 94 | 42 |
 | Wood Stork, Mycteria americana | Fazenda Zelândia (AP) | 01°09' N, 50° 23' W | 12 | 6 | 6 |
 | Wood Stork, Mycteria americana | Fazenda Alegria (AP) | 01°02' N, 50° 32' W | 7 | 5 | 3 |
 | Wood Stork, Mycteria americana | Se Cria (AP) | 01°56' N, 50° 35' W | 68 | 46 | 30 |
 | Roseate Spoonbill, Platalea ajaja | Porto da Fazenda (PAN) | 16 ̊27' S, 56 ̊07' W | 15 | 9 | 7 |
 | Roseate Spoonbill, Platalea ajaja | Praialzinho (PAN) | 16°76' S; 56°58' W | 22 | 14 | 10 |
 | Roseate Spoonbill, Platalea ajaja | Fazenda Zelândia (AP) | 01°09' N, 50°24' W | 23 | 16 | 10 |
 | Roseate Spoonbill, Platalea ajaja | Se Cria (AP) | 01°56' N, 50° 35' W | 50 | 40 | 20 |
 | Roseate Spoonbill, Platalea ajaja | Banhado do Taim (RS) | 32°29' S, 52°35' W | 83 | 68 | 35 |
 | Great Egret, Ardea alba egretta | Porto da Fazenda (PAN) | 16 ̊28' S, 56 ̊ 07' W | 25 | 14 | 12 |
 | Great Egret, Ardea alba egretta | Praialzinho (PAN) | 16°46' S, 56°35' W | 30 | 15 | 15 |
 | Great Egret, Ardea alba egretta | Tucum (PAN) | 16°26' S, 56°03' W | 10 | 5 | 5 |
 | Great Egret, Ardea alba egretta | Barra do Ribeiro (RS) | 30°16' S, 51°23' W | 46 | 35 | 21 | </md>


[User] <|image|>Express the picture as Markdown code.

[Assistant]
<md> | School ID | Total N Year 8 girls | N (%) Opted-out | N (%) Did not participate (other reason) | N (%) consenting Year 8 girls | N (%b) invited to be peer-supporter | N (%a) consenting peer-supporters |
 | --- | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=7> Intervention arm |
 | 2 | 58 | 0 (0.00) | 3 (5.17) | 55 (94.83) | 13 (22.41) | 13 (22.41) |
 | 3 | 96 | 3 (3.13) | 5 (5.21) | 88 (91.67) | 18 (18.75) | 17 (17.70) b |
 | 4 | 66 | 0 (0.00) | 2 (3.03) | 64 (96.97) | 12 (18.18) | 11 (16.67) |
 | 6 | 69 | 0 (0.00) | 7 (10.15) | 62 (89.86) | 14 (20.29) | 14 (20.29) |
 | Total | 289 | 3 (1.04) | 17 (5.88) | 269 (93.07) | 57 (19.72) | 55 (19.03) |
 | <COLSPAN=7> Control arm |
 | 1 | 73 | 1 (1.37) | 0 (0.00) | 72 (98.63) | - | - |
 | 5 | 89 | 0 (0.00) | 3 (3.37) | 86 (96.63) | - | - |
 | Total | 162 | 1 (0.62) | 3 (1.85) | 158 (97.53) | - | - |
 | School mean | 75.16 | 0.67 (0.75) | 3.33 (4.48) | 71.16 (94.68) | 14.25 (19.91) | 13.75 (18.29) |
 | Total | 451 | 4 (0.89) | 20 (4.43) | 427 (94.68) | 57 (19.72) | 55 (19.03) | </md>


[User] <|image|>Convert the table to Markdown syntax.

[Assistant]
<md> | Acquisition Date (DD-MM-YYYY) | Test Site | Pixel Size | No. of Bands |
 | --- | --- | --- | --- |
 | 18-05-1999 | Dresden | 7.7 m | 128 |
 | 18-05-1999 | Potsdam | 4.0 m | 128 |
 | 01-08-2000 | Dresden | 3.3 m | 126 |
 | 20-07-2003 | Dresden | 3.5 m | 126 |
 | 17-06-2007 | Munich | 4.0 m | 125 |
 | 25-06-2007 | Munich | 4.0 m | 125 | </md>


[User] <|image|>Convert the photo into Markdown language.

[Assistant]
<md> | Characteristic | Experiment | Controln = 200 | Test statistic | Pvalue |
 |  | n = 200 [%] | [%] | value (X2) |  |
 | --- | --- | --- | --- | --- |
 | <COLSPAN=5> Sex |
 | Male | 96 (48.0) | 98 (49.0) | 0.04 | 0.84 |
 | Female | 104 (52.0) | 102 (51.0) |  |  |
 | <COLSPAN=5> Age group (months) |
 | < 6 | 31 (15.5) | 36 (18.0) | 6.20 | 0.10 |
 | 6-11 | 37 (18.5) | 28 (14.0) |  |  |
 | 12-23 | 57 (28.5) | 76 (38.0) |  |  |
 | 24-35 | 44 (22.0) | 32 (16.0) |  |  |
 | 36+ | 31 (15.5) | 28 (14.0) |  |  |
 | <COLSPAN=5> Person child shares bed with |
 | Mother | 145 (72.5) | 144 (72.0) | 0.49 | 0.78 |
 | Parents | 49 (24.5) | 52 (26.0) |  |  |
 | Other sibling | 6 (3.0) | 4 (2.0) |  |  | </md>


[User]
<|image|>Parse the following content of the figure in markdown code: <md> | N | D | E | SMR | z | 95% CI |
 | --- | --- | --- | --- | --- | --- |
 | Total, n = 1400 | 38 | 16.11 | 236 | 5.45 | 167–324 |
 | Males, n = 667 | 24 | 10.61 | 226 | 4.11 | 145–337 |
 | Females,

[Assistant] n = 733 | 14 | 5.50 | 255 | 3.62 | 139–427 | </md>


[User] <|image|>Express the table as Markdown code.

[Assistant]
<md> | Income grade | UEBMI | URBMI | NCMS |
 | --- | --- | --- | --- |
 | I | ≤2500 | ≤1200 | ≤350 |
 | II | 2501–3520 | 1201–2000 | 351–800 |
 | III | 3521–4500 | 2001–2800 | 801–1370 |
 | IV | 4501–5600 | 2801–4000 | 1371–2500 |
 | V | >5600 | >4000 | >2500 | </md>


[User] <|image|>Convert the illustration to Markdown syntax.

[Assistant]
<md> |  |  |  | Neutralization |
 | Epitope cluster | Clone name | Epitope determinantsa | (ND50; pM)b |
 | --- | --- | --- | --- |
 | A | GZ4 | A | 3500 |
 | A | 1-D1K | A | 390 |
 | A | MT126L | A | >13000 |
 | A | 45F | a,F | 1400 |
 | A | 30S | a,c,D | — |
 | E | 111W | E | 40 |
 | E | 42H | E | 53 |
 | E | 40K | b,d,E | 390 |
 | E | 7-B6-1 | E | 120 |
 | E | 124i | b,d,E | 9100 |
 | Other | G23 | B,C,f,CT | — |
 | Other | 11i | a,D | — | </md>


[User] <|image|>Express the table as Markdown code.

[Assistant]
<md> |  |  | <COLSPAN=2> Focal segmental glomerulosclerosis | <COLSPAN=2> Proliferative LN(class III or IV) | <COLSPAN=2> Pure membranous LN (class V) |
 |  |  | n of 10 (%) | Median (Range) | n of 7 (%) | Median (Range) | n of 7 (%) | Median (Range) |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | Females |  | 3 (33%) |  | 4/7 (57%) |  | 5/7 (71%) |  |
 | Race | Black | 2/10 (20%) |  | 3/7 (42%) |  | 3/7 (42%) |  |
 |  | White | 5/10 (50%) |  | 2/7 (29%) |  | 2/7 (29%) |  |
 |  | Other | 3/10 (30%)* |  | 2/7 (29%)† |  | 3/7 (43%)** |  |
 | Medications | Oral prednisone | 4/10 (40%) |  | 7/7 (100%) |  | 4/7 (57%) |  |
 |  | Mycophenolate mofetil | 5/10 (50%) |  | 3/7 (43%) |  | 5/7 (71%) |  |
 |  | Cyclophosphamide | - |  | 2/7 (29%) |  | 1/7 (14%) |  |
 |  | Angiotensin blocking agent | 9/10 (90%) |  | 2/7 (29%) |  | 6/7 (86%) |  |
 | Kidney Status | GFR < 60 ml/min/m2 | 4/10 (40%) |  | 1/7 (14%) |  | 1/7 (14%) |  |
 |  | Protein: creatinine ratio > 0.5 | 5/5 (100%) |  | 7/7 (100%) |  | 7/7 (100%) |  |
 |  | Renal SDI score > 0¥ | - |  | 0/3 |  | 1/4 (25%) |  |
 |  | Renal SLEDAI score‡ | - |  |  | 4 (0-16) |  | 8 (4-12) |
 |  | Presence of anti double-stranded-dsDNA | - |  | 7/7 (100%) |  | 4/7 (67%) |  | </md>


[User] <|image|>Interpret the diagram as Markdown format.

[Assistant]
<md> | Herds | No. of positive sera | No. of sera examined |
 | --- | --- | --- |
 | 1 | 10 | 10 |
 | 2 | 10 | 10 |
 | 3 | 14 | 16 |
 | 4 | 17 | 24 |
 | 5 | 62 | 92 |
 | Total | 113 | 152 | </md>


[User] <|image|>Convert the photo into Markdown language.

[Assistant]
<md> | Study EFPIA partner | Results current process | Results EHR4CR PF system | Gold Standard-Mean [LB – HB] | Patients per clinic |
 | --- | --- | --- | --- | --- |
 | NCT00439725 Bayer | 20 | 205 | 494 [288 – 816] | 4116 |
 | NCT00638690 Janssen | 25 | 5 | 86 [15 – 470] | 8626 |
 | NCT00626548 AstraZeneca | 250 | 695 | 1035 [603 – 1709] | 8626 | </md>


[User]
<|image|>What are the following diagram content in markdown style: <md> | <ROWSPAN=2> Diagnosis | <COLSPAN=2> Cases |
 | No. | % |
 | --- | --- | --- |
 | Tuberculosis—all | 25 | 23 |
 | Pulmonary | 16 |  |
 | Disseminated | 5 |  |
 | TB meningitis | 2 |  |
 | Lymph node | 1 |  |
 | Joint | 1 |  |
 | Pulmonary infection | 12 | 11 |
 | Candidiasis—all | 11 | 10 |
 | Oral | 3 |  |
 | Oesophageal | 5 |  |
 | Vulvovaginal | 3 |  |
 | Pregnancy-related admission | 8 | 7.3 |
 | Skin—all | 8 | 7.3 |
 | Fungal | 4 |  |
 | Drug rash | 3 |  |
 | Infestation (scabies) | 1 |  |
 | Abscess/cellulitis | 6 | 5.5 |
 | CMV disease—all | 4 | 3.7 |
 | CMV retinitis | 3 |  |
 | CMV colitis | 1 |  |
 | Sepsis | 5 | 4.6 |
 | Herpes Zoster | 3 | 2.8 |
 | Malignancy—all | 3 | 2.8 |
 | Kaposi sarcoma | 1 |  |
 | Poorly-differentiated carcinoma of tongue | 1 |  |
 | Infantile fibrosarcoma | 1 |  |
 | Peripheral

[Assistant]
neuropathy | 3 | 2.8 |
 | Disseminated histoplasmosis | 2 | 1.8 |
 | Cryptosporidiosis | 1 | 0.9 |
 | Shigellosis | 1 | 0.9 |
 | Bacterial meningitis | 1 | 0.9 |
 | Recurrent otitis media | 1 | 0.9 | </md>


[User] <|image|>Transform the table into Markdown format.

[Assistant]
<md> | Gene | rs # | Chromosome | Allele (major/minor) | Position | HWE in controls |
 | --- | --- | --- | --- | --- | --- |
 | XPA | rs1800975 | 9:97697296 | G/A | 5' non-coding region (-4A/G) | 0.118/2.445 |
 | ERCC1 | rs11615 | 19:45420395 | C/T | Exon 4 (Asn118Asn) | 0.509/0.436 |
 | XPC | rs2228000 | 3:14158387 | C/T | Exon 9 (Ala499Val) | 0.498/0.460 |
 | XPC | rs2228001 | 3:14145949 | A/C | Exon 16 (Gln939Lys) | 0.267/1.231 |
 | ERCC2/XPD | rs238406 | 19:45365051 | G/T | Exon 6 (Arg156Arg) | 0.766/0.088 |
 | ERCC2/XPD | rs1799793 | 19:45364001 | G/A | Exon 10 (Asp 312 Asn) | 0.101/2.687 |
 | ERCC2/XPD | rs50872 | 19:45359191 | C/T | Intron 12 | 0.945/0.005 |
 | ERCC2/XPD | rs13181 | 19:45351661 | T/A | Exon 23 ( Lys751 Gln) | 0.716/0.132 |
 | ERCC2/XPD | rs3810366 | 19:45370684 | C/G | Promoter (-114) | 0.099/2.728 |
 | ERCC4/XPF | rs1799801 | 16:13948101 | T/C | Exon 11 (Ser835Ser) | 0.619/0.247 |
 | ERCC5/XPG | rs17655 | 13:102875652 | C/G | Exon 15 (His1104Asp) | 0.077/3.137 | </md>


[User] <|image|>Transform the picture into Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Characteristics | <COLSPAN=2> S. aureus colonization | <ROWSPAN=2> Total |
 | Yes | No |
 | --- | --- | --- | --- |
 | <COLSPAN=4> Age |
 | Median | 6 | 5 | 5 |
 | Range | 3 | 3 | 3 |
 | <COLSPAN=4> Age (years) |
 | > 4 | 48 (12%) | 248 (62%) | 296 (74%) |
 | ≤ 4 | 4 (1%) | 100 (25%) | 104 (26%) |
 | Total | 52 (13%) | 348 (87%) | 400 (100%) |
 | <COLSPAN=4> Sex |
 | Male | 20 (5%) | 140 (35%) | 160 (40%) |
 | Female | 32 (8%) | 208 (52%) | 240 (60%) |
 | Total | 52 (13%) | 348 (87%) | 400 (100%) | </md>


[User]
<|image|>What are the following illustration content in markdown style: <md> | Gene | Sequence |
 | ---

[Assistant]
| --- |
 | Cytokeratin14 | 5′-GTCCTTCTGCAGATTGACAATGA-3′ (forward)5′-TTCACCAAGACAGAGGAGCTGAA-3′ (reverse) |
 | E-cadherin | 5′-GAAGATTGCACCGGTCGACAAA-3′ (forward)5′-CCACCAAAGTCACGCTGAATAC-3′ (reverse) |
 | ΔNp63 | 5′-CAGACTCAATTTAGTGAG-3′ (forward)5′-AGCTCATGGTTGGGGCAC-3′ (reverse) |
 | Amelogenin | 5′-GGAGCAGCTTTTGCCATGCCT-3′ (forward)5′-GTGGCCTTATGCTCTGGTAC-3′ (reverse) |
 | GAPDH | 5′-GAGTCAACGGATTTGGTCGT-3′ (forward)5′-GACAAGCTTCCCGTTCTCAG-3′ (reverse) | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> | Software | Type | Input data and format | discordant reads detection | transposition calling | Every potential mapping considered | Detection of unknow TEs insertion | Precision | Donor/Acceptor output |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | TE-Tracker |  | BAM file | ✓ | ✓ | ✓ | ✓ | 100 bp-1 Kbp | ✓ |
 | RetroSeq | TE-dedicated | BAM file, TE annotation or sequence | ✓ | ✓ | ✗ | ✗ | 100 bp-1 Kbp | ✓ |
 | Tea | TE-dedicated | BAM file, TE annotation or sequence | ✗ | ✓ | ✗ | ✗ | 1 bp | ✓ |
 | T-lex |

[Assistant]
TE-dedicated | FASTQ file, TE annotation | ✗ | ✓ | ✗ | ✗ | 1 bp | ✓ |
 | Popoolation-TE | TE-dedicated | FASTQ file, TE sequence and TSD annotation | ✗ | ✓ | ✗ | ✗ | 1 bp | ✓ |
 | TE-locate | TE-dedicated | FASTQ file, TE sequence | ✗ | ✓ | ✗ | ✗ | 1 bp | ✓ |
 | ngs_te_mapper | TE-dedicated | FASTQ file, TE annotation | ✗ | ✓ | ✓ | ✗ | 1 bp | ✓ |
 | RelocatTE | TE-dedicated | FASTQ file, TE sequence | ✗ | ✓ | ✓ | ✗ | 1 bp | ✓ |
 | TIF | TE-dedicated | FASTQ file, TE sequence and TSD annotation | ✗ | ✓ | ✗ | ✗ | 1 bp | ✓ |
 | VariationHunter | SV | DIVET alignment file (mrFAST output) | ✗ | ✗ | ✓ | ✓ | 100 bp-1 Kbp | ✓ |
 | PRISM | SV | BAM file | ✓ | ✗ | ✗ | ✓ | 1 bp | ✗ |
 | Delly | SV | BAM file | ✓ | ✗ | ✗ | ✓ | 1 bp | ✗ |
 | GASVpro | SV | Alignment file and coverage data file | ✓ | ✗ | ✓ | ✓ | 100-1 kp | ✗ |
 | Hydra | SV | Discordant reads coordinates and mapping features | ✗ | ✗ | ✓ | ✓ | 1 bp | ✗ | </md>


[User]
<|image|>Parse the following content of the figure in markdown code: <md> | Clinical pharmacology classification | N | Price change (%) |
 | --- | --- | --- |
 | Antiallergics | 121 | −60.3 |
 | Blood-related medicine | 317 | −52.6 |
 | Water-Electrolyte-Acid–base-Balance Medicine | 842 | −49.2 |
 | Antiparasitics | 218 | −48.9 |
 | Urinary system medicine | 152 | −48.8 |
 | Antimicrobial medicine | 1643 | −46.9 |
 | Gynecological medicine | 94 | −46.7 |
 | Vitamin & mineral supplements | 519 | −43.6 |
 | Antipsychotics | 70 | −42.3 |
 | Ophthalmic medicine | 177 | −40.0 |
 | Dermatologic medicine | 291 | −39.5 |
 | Nervous system medicine | 298 | −39.1 |
 | Digestive system medicine | 842 | −38.9 |
 | Respiratory system medicine | 333 | −37.5 |
 | Hormone | 489 | −34.8 |
 | Ear, nose, and throat medicine | 38 | −29.6 |
 | Antipyretic-analgesic

[Assistant]
and anti-inflammatory medicine | 426 | −29.4 |
 | Cardiovascular system medicine | 805 | −28.3 |
 | Biological medicine | 72 | 72.2 |
 | Others | 151 | −50.0 | </md>


[User]
<|image|>Parse the following content of the picture in markdown code: <md> | Group | N | Excellence | Effective | Invalid | P |
 | --- | --- | --- | --- | --- | --- |
 | Male | 118 | 37 | 61 | 20 | 0.4569 |
 | Female |

[Assistant] 82 | 25 | 42 | 15 | 0.4491 | </md>


[User]
<|image|>What are the following table content in markdown style: <md> | <ROWSPAN=2> Sample | <COLSPAN=5> Percentage of contribution of standard spectra (%) |
 | Pyrite | Elemental sulfur | Sulfate | Jarosite | DBT |
 | --- | --- | --- | --- | --- | --- |
 | Raw coal | 45.64 | 0 | 23.57 | 0 | 14.34 |
 | Residual coal (16 days) | 35.67 | 28.32 | 10.16 | 18.99

[Assistant]
| 13.86 |
 | Raw pyrite | 100 | 0 | 0 | 0 | 0 |
 | Residual pyrite (24 days) | 49.34 | 50.72 | 0 | 0 | 0 | </md>


[User] <|image|>Transform the picture into Markdown format.

[Assistant]
<md> | Expert | Sensitivity % | Specificity % | PPV % | NPV % |
 | --- | --- | --- | --- | --- |
 | 1 | 100 (50/50) | 95.6 (43/45) | 96.2 (50/52) | 100 (43/43) |
 | 2 | 86.0 (43/50) | 97.8 (44/45) | 97.7 (43/44) | 86.3 (44/51) |
 | 3 | 100 (50/50) | 73.3 (33/45) | 80.6 (50/62) | 100 (33/33) |
 | Averaged | 95.3 (143/150) | 88.9 (120/135) | 90.5 (143/158) | 94.5 (120/127) | </md>


[User] <|image|>Express the table as Markdown code.

[Assistant]
<md> | Date | T-score | Treatment |
 | --- | --- | --- |
 | November 2002 | Greater than −2.5 | ERT |
 | December 2003 | −1/-2.5 | ERT |
 | July 2005 | −1/−2.5 | ERT |
 | May 2006 | −1/−2.5 | ERT |
 | May 2008 | −1/−2.5 | SRT |
 | March 2011 | −1.5 | SRT |
 | April 2012 | −1.5 | SRT | </md>


[User]
<|image|>Parse the image content behind with markdown code: <md> |  | Number | Percent |  | Number | Percent |  |
 | --- | --- | --- | --- | --- | --- | --- |
 | AGE |  |  | AWAREP |  |  |  |
 | 16–25 | 109 | 12.1 | Yes | 271 | 29.88 |  |
 | 26–35 | 196 | 21.7 | No | 13 | 1.43 |

[Assistant]
|
 | 36–45 | 237 | 26.2 | Don’t Know | 623 | 68.69 |  |
 | 46–55 | 200 | 22.1 | AWAREPC |  |  |  |
 | 56–65 | 101 | 11.2 | Yes | 68 | 7.71 |  |
 | 66+ | 61 | 6.7 | No | 112 | 12.7 |  |
 | GENDER |  |  | Don’t Know | 702 | 79.59 |  |
 | Male | 312 | 33.8 | VIRALHEP |  |  |  |
 | Female | 612 | 66.2 | Yes | 647 | 70.94 |  |
 | OCCUPATION |  |  | No | 213 | 23.36 |  |
 | Labourer | 192 | 21.4 | Don’t Know | 52 | 5.7 |  |
 | Unemployed | 247 | 27.5 | PATIENT |  |  |  |
 | Retired | 131 | 14.6 | I hear | 397 | 43.44 |  |
 | Self-employed /B.O/P.S.Worker | 327 | 36.5 | I don’t hear | 404 | 44.2 |  |
 | INTERNET |  |  | Don’t Know | 113 | 12.36 |  |
 | Yes | 559 | 63 | HISTofHBV |  |  |  |
 | No | 329 | 37.1 | Yes | 102 | 11.26 |  |
 | CELLPHONE |  |  | No | 654 | 72.19 |  |
 | Yes | 878 | 97 | Don’t Know | 150 | 16.56 |  |
 | No | 27 | 2.98 |  | Obs | Mean | Std. Dev. |
 | MIGRANT |  |  | ROOM | 905 | 3.3 | 0.75 |
 | Yes | 382 | 57.5 | PEOPLE | 898 | 3.53 | 1.22 |
 | No | 517 | 42.5 |  |  |  |  |
 | MIG_EAST |  |  |  |  |  |  |
 | Yes | 118 | 87.2 |  |  |  |  |
 | No | 806 | 12.8 |  |  |  |  | </md>


[User] <|image|>Express the illustration as Markdown code.

[Assistant]
<md> | <ROWSPAN=2> Kappa[95% CI] | <ROWSPAN=2> N | <COLSPAN=3> Agree | <ROWSPAN=2> Disagreen (%) |
 | Overalln (%) | Narrown | Openn |
 | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=6> Visit 1 |
 | 0.66[0.50, 0.83] | 86 | 73 (85%) | 22 | 51 | 13 (15%) |
 | <COLSPAN=6> Visit 2 |
 | 0.69[0.50, 0.89] | 71 | 63 (89%) | 13 | 50 | 8 (11%) | </md>


[User]
<|image|>Parse the photo content behind with markdown code: <md> |  | AS-SMP3 days(N = 476) | AS-SMP24 hours(N = 458) | AL3 days(N = 450) |
 | --- | --- | --- | --- |

[Assistant]
| Age (Years) |  |  |  |
 | Median | 8.0 | 9.0 | 8.0 |
 | Min, Max | 0.4, 63.5 | 0.6, 79.0 | 0.6, 60.0 |
 | Age Group (Years) |  |  |  |
 | < 5 – n (%) | 153 (32.1) | 123 (26.9) | 137 (30.4) |
 | Gender |  |  |  |
 | Male – n (%) | 239 (50.3) | 226 (49.3) | 223 (49.6) |
 | P. falciparum (/μl) |  |  |  |
 | Median (IQR) | 8400 (3180–24160) | 8000 (3200–19520) | 7600 (3120–28140) |
 | Gametocyte carriage – n (%) | 6 (1.3) | 16 (3.5) | 8(1.8) |
 | Fever prevalence* – n (%) | 332(69.7) | 324(70.7) | 316(70.2) | </md>


[User] <|image|>Convert the illustration into Markdown language.

[Assistant]
<md> | State or Message | Description a |
 | --- | --- |
 | Candidate | The node is a candidate node |
 | Head | The node is selected as cluster head |
 | Plain | The node is a member node |
 | Compete_Msg | Composed by the ID of sender |
 | Join_Msg | Composed by the ID of sender and the ID of head |
 | Weight_Msg | Composed by the ID of sender, weight, Ea, Eresidual |
 | Schedule_Msg | Head assign slot time for its member nodes | </md>


[User]
<|image|>Parse the photo content behind with markdown code: <md> | ID | NDBp Family | Length of the Mature Peptide | Hydrophobicity | Hydrophobic Moment | Charge |
 | --- | --- | --- | --- | --- | --- |
 | TatHDPND202 | NDBP-2 | 47 | 0.263 | 0.065 | +6 |
 | TatHDPND201 | NDBP-2 | 43 | 0.212 | 0.089 | +6 |
 | TatHDPND301 | NDBP-3 | 19 | 0.903 | 0.377 | +2 |
 | TatHDPND302 | NDBP-3 | 25 | 0.495 | 0.327

[Assistant]
| +4 |
 | TatHDPND405 | NDBP-4 | 13 | 0.819 | 0.606 | +1 |
 | TatHDPND406 | NDBP-4 | 13 | 0.742 | 0.458 | +1 |
 | TatHDPND407 | NDBP-4 | 13 | 0.746 | 0.456 | +1 |
 | TatHDPND402 | NDBP-4 | 13 | 0.778 | 0.779 | 0 |
 | TatHDPND403 | NDBP-4 | 13 | 0.752 | 0.792 | +1 |
 | TatHDPND401 | NDBP-4 | 13 | 0.793 | 0.595 | +1 | </md>


[User] <|image|>Convert the illustration to Markdown syntax.

[Assistant]
<md> |  |  | Group A (≤10 deg.; n = 22) | Group B (≥11 deg.; n = 30) | p value |
 | --- | --- | --- | --- | --- |
 | Age | (years) | 67.9 ± 8.3 | 67.5 ± 11.8 | NS |
 | Sex | (M/F) | 14/8 | 11/19 | NS |
 | Body mass index | (kg/m2) | 23.7 ± 2.6 | 25.4 ± 3.9 | NS |
 | Degenerative scoliosis | (≥10 deg) | 22.7 % (5/22) | 40.0 % (12/30) | NS |
 | Diabetes mellitus |  | 0.0 % (0/22) | 10.0 % (3/30) | NS |
 | Depression |  | 4.5 % (1/22) | 6.7 % (2/30) | NS |
 | Pelvic incidence (PI)a | (Degree) | 44.9 ± 7.0 | 52.1 ± 11.7 | p = 0.013 |
 | Lumbar lordosis (LL)a | (Degree) | 44.0 ± 8.3 | 29.4 ± 10.7 | p < 0.001 |
 | PI minus LL (PI-LL)a | (Degree) | 1.0 ± 5.8 | 22.7 ± 8.9 | p < 0.001 |
 | Follow-up | (months) | 16.9 ± 6.6 | 15.9 ± 5.3 | NS | </md>


[User]
<|image|>What are the following image content in markdown style: <md> | <ROWSPAN=2> Characteristics | <COLSPAN=2> Frequency (%) and median (IQR) |
 | County hospital (n=234) | Township hospital (n=480) | Total (n=714) |
 | --- | --- | --- |
 | Access to blood culture | 150 (64.1) | 257 (53.5) | 407 (57.0) |
 | Medical expense for illness† (median, IQR) | 263.9 (190.8, 389) | 264 (176.7,

[Assistant]
460.5) | 264 (180.1, 424.2) |
 | Percentage of reimbursement for all types of payment (%) |  |  |  |
 | 0–10 | 193 (82.5) | 196 (40.8) | 389 (54.5) |
 | 11–50 | 21 (9) | 240 (50) | 261 (36.6) |
 | 51–100 | 20 (8.5) | 44 (9.2) | 64 (9) | </md>


[User]
<|image|>Parse the following content of the image in markdown code: <md> | Language | Method | # exp. | # correct | Precision | Recall | F1 |
 | --- | --- | --- | --- | --- | --- | --- |
 | <ROWSPAN=5> Chinese | GUTime | 512 | 429 | 0.838 | 0.241 | 0.375 |
 | HeidelTime | 954 | 824 | 0.864 | 0.463 | 0.603 |
 | CMedTEX | 2293 | 1645 | 0.717 | 0.925 | 0.808 |
 | TEER_C | 1761 | 1613 | 0.916 | 0.907 | 0.912 |
 | TEER | 1761 | 1657 | 0.941 | 0.932 | 0.936 |
 | <ROWSPAN=6> English | NLTK Timex | 106 | 61 | 0.575 | 0.153 | 0.242 |
 | GUTime | 101

[Assistant]
| 88 | 0.871 | 0.221 | 0.353 |
 | IllinoisTExtractor | 352 | 287 | 0.815 | 0.721 | 0.765 |
 | Heideltime | 395 | 327 | 0.828 | 0.822 | 0.825 |
 | TEXer | 360 | 340 | 0.944 | 0.854 | 0.897 |
 | TEER | 368 | 349 | 0.948 | 0.877 | 0.911 | </md>


[User] <|image|>Render the illustration in Markdown format.

[Assistant]
<md> | Groups | Standard Lab Chow (LC) | Safflower oil (SO) |
 | Research diets | D10012M (AIN-93M) | D11102001 |
 |  | g % | g % |
 | --- | --- | --- |
 | Protein | 14 | 15 |
 | Carbohydrate | 73 | 66 |
 | Fat | 4 | 10 |
 | Omega-3 fatty acids | 0.011 | 0.015 |
 | Omega-6 fatty acids | 3.1 | 6.63 |
 | Omega-9 fatty acids | 0.9 | 1.34 |
 | Kcal/g | 3.8 | 4.2 | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> |  | Early Surveys(2000-2004)N=108 | Late Surveys(2006-2013)N=116 | p value |
 | --- | --- | --- | --- |
 | Gender (female) | 28.7% | 31% | 0.7 |
 | Median Age | 70.52±13.67 | 68.95±13.22 | 0.35 |
 | Age above >75 years | 47.22% | 38.79% | 0.2 |
 | <COLSPAN=4> Cardiovascular risk factor and cardiovascular history |
 | History of Diabetes | 28% | 41.7% | 0.03 |
 | History of HTN | 50.5% | 64.9% | 0.029 |
 | History of dyslipidemia | 31.8% | 63.6% | 0.001 |
 | Family history of CAD | 10.3% | 18.1% | 0.11 |
 | Mean BMI | 26.43±4.49 | 27.68±5.29 | 0.23 |
 | History of MI | 33.6% | 30.1% | 0.57 |
 | Past PCI | 29.9% | 7.8% | 0.1 |
 | Past

[Assistant]
CABG | 4.7% | 21.2% | 0.33 |
 | Past CAV/TIA | 19.4% | 8.8% | 0.02 |
 | History of CHF | 13.1% | 16.8% | 0.58 |
 | History of CRF | 13.9% | 14.9% | 0.82 |
 | History of PVD | 13.1% | 10.6% | 0.57 |
 | <COLSPAN=4> Chronic Medication |
 | ASA | 52.5% | 44.9% | 0.34 |
 | Clopidogrel | 1.6% | 5.7% | 0/19 |
 | BB | 38.1% | 39.8 | 0.82 |
 | ACEi | 28.6% | 38.1% | 0.2 |
 | CCB | 19.4% | 18.9% | 0.92 |
 | Nitrate | 28.6% | 9.4% | 0.001 |
 | Lipid lowering agents | 15.7% | 37.1% | 0.0003 |
 | Insulin | 3.2% | 4.5% | 0.65 |
 | Anti-Hyperglycemic | 15.9 | 29.5 | 0.04 | </md>


[User]
<|image|>Parse the following content of the diagram in markdown code: <md> | <ROWSPAN=2> Subject | <COLSPAN=2> Body weighta | <COLSPAN=2> Body weight versus dayb |
 | CV (%) | SD (kg) | Slope | Intercept (R2) |
 | --- | --- | --- | --- | --- |
 | A | 0.25 | 0.16 | −20.0 | 66.2 (0.14) |
 | B | 0.53 | 0.36 | 6.2 | 63.4 (0.32)* |
 | C | 0.31 | 0.16 | 21.8 | 52.6 (0.16) |
 | D | 0.44 | 0.33 | 41.2 | 76.2 (0.14)

[Assistant]
|
 | E | 0.34 | 0.31 | 1.8 | 89.7 (0.001) |
 | F | 0.39 | 0.42 | −103.0 | 108.1 (0.55)** |
 | Mean ± SD | 0.38 ± 0.10 | 0.29 ± 0.10 | 1.0 | 76.0 (0.0002) | </md>


[User] <|image|>Translate the picture into Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Toothpaste | <COLSPAN=3> Dose (mg F/day/Kg bw) |
 | Based on declared TF | Based on measured TF | Based on measured TSF |
 | --- | --- | --- | --- |
 | Family * (n = 80) | 0.074 ± 0.007 A,a | 0.074 ± 0.007 A,a | 0.039 ± 0.005 A,b |
 | Children’s ** (n = 78) | 0.040 ± 0.007 B,a | 0.039 ± 0.003 B,a | 0.039 ± 0.005 A,a |
 | All (n = 158) | 0.057 ± 0.004 a | 0.057 ± 0.004a | 0.039 ± 0.003 b | </md>


[User]
<|image|>Parse the following content of the photo in markdown code: <md> |  | 5 | 4S | 4F | 3 | 2 | 1 | 6 |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | 5 | −1.7679 | 0.0000 | 0.0000 | 0.3896 | 0.0740 | 0.0000 | 1.3043 |
 | 4S | 0.0000 | −1.1958 | 0.0000 | 0.3629 | 0.4395 | 0.2703 | 0.1232 |
 | 4F | 0.0000 | 0.3316 | −1.5274 | 0.3629 | 0.4395 | 0.2703 | 0.1232 |
 | 3 | 0.0000 | 0.0000 | 1.4000 | −2.3300 | 0.0000 | 0.0000 | 0.9300 |

[Assistant]
 | 2 | 0.0000 | 0.0000 | 2.4000 | 0.0000 | −2.5500 | 0.0000 | 0.1500 |
 | 1 | 0.0000 | 0.0000 | 1.3300 | 0.0000 | 0.0000 | −1.4400 | 0.1100 |
 | 6 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 1.0000 | </md>


[User] <|image|>Express the photo as Markdown code.

[Assistant]
<md> | Characteristic | Support(n = 105) | Control(n = 107) |
 | --- | --- | --- |
 | Age [mean in years (range)] | 20.6 (13–42) | 20.1 (14–36) |
 | In a stable union (n) | 80 (76.2%) | 92 (85.9%) |
 | Secondary education (n) | 103 (98.1%) | 106 (99.1%) |
 | Religious (n) | 96 (91.4%) | 100 (93.4%) |
 | Non-white skin color (n) | 79 (75.2%) | 75 (70.1%) |
 | Housewife (n) | 63 (60.0%) | 67 (62.6%) |
 | Start of prenatal care (GA < 28 weeks) (n) | 101 (96.2%) | 103 (96.3%) |
 | Number of prenatal visits ≥ 6 (n) | 84 (85.0%) | 84 (78.5%) |
 | Accompanied during prenatal care (n) | 44 (41.9%) | 54 (50.5%) |
 | Participated in classes for pregnant women (n) | 16 (15.2%) | 16 (14.9%) |
 | Gestational age at delivery [mean in weeks (range)] | 39.2 (37–42) | 39.0 (37–42) |
 | Cervical dilation at admission [mean in cm (range)] | 3.9 (3–6) | 3.9 (3–6) |
 | Cervical effacement ≥ 80% (n) | 75 (71.4%) | 68 (63.6%) |
 | Intact amniotic membrane (n) | 82 (78.1%) | 83 (77.6%) | </md>


[User] <|image|>Convert the figure into Markdown format.

[Assistant]
<md> | Description | Version 2.3 | Version 2.5p1 | Version 2.5.2 |
 | --- | --- | --- | --- |
 | No. of reads used for assembly | 304,619 | 303,601 | 303,601 |
 | No. of reads assembled in to contigs | 248,857 | 247,757 | 247,757 |
 | No. of contigs assembled | 17, 613 | 17,457 | 17,457 |
 | No. of singletons | 54,669 | 54,002 | 54,002 |
 | Average contig length (bases) | 909 | 916 | 916 |
 | Largest contig length (bases) | 7,170 | 7,173 | 7,173 | </md>


[User] <|image|>Translate the figure into Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Variables | <COLSPAN=2> Frequency n (%) |
 | Yes n (%) | No n (%) |
 | --- | --- | --- |
 | HIV can be sexually transmitted | 500 (99.6) | 2(0.4) |
 | HIV can be transmitted through Blood transfusion | 499(99.4) | 3(0.6) |
 | HIV can be transmitted from mother to child | 477(95.0) | 25(5.0) | </md>


[User] <|image|>Encode the diagram in Markdown syntax.

[Assistant]
<md> | <ROWSPAN=2> Mature miRNA | Control | Infected |
 | % | % |
 | --- | --- | --- |
 | miR-21-5p | 17.1 | 24.5 |
 | miR-143-3p | 11.4 | 7.8 |
 | miR-126-3p | 8.3 | 5.7 |
 | miR-26a-5p | 6.2 | 6.5 |
 | miR-148a-3p | 6.1 | 2.9 |
 | let-7f-5p | 4.1 | 4.2 |
 | let-7g-5p | 3.7 | 5.3 |
 | let-7a-5p | 2.8 | 2.6 |
 | let-7i-5p | 2.8 | 4.2 |
 | miR-99a-5p | 2.6 | 2.7 |
 | miR-10a-5p | 2.1 | 1.1 |
 | miR-100-5p | 2.1 | 1.3 |
 | miR-199a-3p | 1.5 | 1.3 |
 | miR-146b-5p | 1.3 | 1.3 |
 | miR-191-5p | 1.2 | 1.4 |
 | miR-24-3p | 1.1 | 1.1 |
 | miR-181a-5p | 1 | 1.3 |
 | miR-27b-3p | 1 | 1 |
 | miR-30d-5p | 1 | – |
 | miR-142-5p | 0.9 | – |
 | miR-150-5p | – | 1.4 |
 | miR-92a-3p | – | 1.1 | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> | Input Signals | Explanation |
 | --- | --- |
 | grfL | vertical ground reaction force of the left foot (N) |
 | grfR | vertical ground reaction force of the right foot (N) |
 | grfDiff | average absolute difference between grfL and

[Assistant]
grfR in the past 50 samples (N) |
 | COPyL | longitudinal coordinate of the center of pressure for the left foot (starting from the toes to the heel) (mm) |
 | COPyR | longitudinal coordinate of the center of pressure for the right foot (starting from the toes to the heel) (mm) |
 | sumAng | the sum of all knee and hip angles (°) |
 | gyroL | angular velocity of the left foot in the sagittal plane (rad/s) |
 | gyroR | angular velocity of the right foot in the sagittal plane (rad/s) | </md>


[User] <|image|>Encode the figure in Markdown syntax.

[Assistant]
<md> | GenBank No. | Submission No. | Species |
 | --- | --- | --- |
 | KJ440515 | 1698905 | Dog - Canis lupus familiaris |
 | KJ440516 | 1698976 | Dog - Canis lupus familiaris |
 | KJ440517 | 1698981 | Louse - Linognathus setosus |
 | KJ440518 | 1698985 | Louse - Linognathus setosus |
 | KJ440519 | 1698989 | Mosquito - Anopheles sinensis |
 | KJ440520 | 1699024 | Mosquito - Culex pipiens pallens |
 | KJ440521 | 1699027 | Tick - Rhipicephalus sanguineus |
 | KJ440522 | 1699029 | Louse - Linognathus setosus |
 | KJ440523 | 1699030 | Mosquito - Anopheles sinensis | </md>


[User]
<|image|>Continue parse the diagram with markdown style: <md> | Exon | Primers |
 | --- | --- |
 | 24 | Ex24-1F: 5’-GGGGCTCTCTGTGCTTCTGGAAACT-3’ |
 |  |

[Assistant]
Ex24-1R: 5’-ACAAAGGGGGCCTGGGTTCGGAATC-3’ |
 | 24 | Ex24-2F: 5’-TGAGACGTTCCAGGCCAGCACAGT-3’ |
 |  | Ex24-2R: 5’-GACCTCAGGTCTCACCCTCTAAGG-3’ |
 | 27 | Ex27-1F: 5’-CTGAAGCTGATAGAGGTGGGCCATC-3’ |
 |  | Ex27-1R: 5’-TTGAAGGACACGCCCTGCACAGCCA-3’ |
 | 27 | Ex27-2F: 5’-GGGACTTTGGGCTAAGATACCGACC-3’ |
 |  | Ex27-2R: 5’CCTGGAGTCCTTTGGCCTAAACTCC-3’ | </md>


[User] <|image|>Transcribe the figure into Markdown format.

[Assistant]
<md> |  | TTH with insomnia, N = 75 | TTH without insomnia, N = 495 | P |
 | --- | --- | --- | --- |
 | <COLSPAN=4> Demographics |
 | Age, Mean ± SD (years) | 44.5 ± 13.7 | 42.5 ± 13.7 | 0.236 |
 | Women, N (%) | 43 (57.3) | 259 (52.3) | 0.418 |
 | <COLSPAN=4> Headache characteristics |
 | Bilateral pain, N (%) | 45 (60.0) | 329 (66.5) | 0.272 |
 | Non-pulsating quality, N (%) | 29 (38.7) | 198 (40.0) | 0.824 |
 | Mild-to-moderate severity, N (%) | 73 (97.3) | 490 (99.0) | 0.225 |
 | Non-aggravation by movement, N(%) | 58 (77.3) | 393 (79.4) | 0.682 |
 | <COLSPAN=4> Associated symptoms |
 | Photophobia, N (%) | 6 (8.0) | 40 (8.1) | 0.981 |
 | Phonophobia, N (%) | 31 (41.3) | 150 (30.3) | 0.056 |
 | Headache frequency, Median (IQR) | 1.0 (0.3–3.0) | 0.4 (0.2–1.0) | 0.002a |
 | VAS score, Median (IQR) | 5.0 (4.0–7.0) | 4.0 (3.0–6.0) | < 0.001a |
 | HIT-6 score, Median (IQR) | 46.0 (40.0–52.0) | 42.0 (38.0–46.0) | < 0.001a |
 | Anxiety, N (%) | 21 (28.0) | 33 (6.7) | < 0.001 |
 | Depression, N (%) | 16 (21.3) | 8 (1.6) | < 0.001 | </md>


[User]
<|image|>Continue parse the image with markdown style: <md> | Species | Fat [g/100 g] |
 | --- | --- |
 | Giant mealworm larva | 35 ± 0.1 a |
 | Common mealworm

[Assistant]
pupa | 32 ± 0.5 a |
 | Common mealworm larvae | 31 ± 1.1 a |
 | Field cricket nymph | 32 ± 0.2 a | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> | <ROWSPAN=2> Concept | <ROWSPAN=2> Measurement | <ROWSPAN=2> Items | <COLSPAN=4> Moment in time |
 | 3-monthly diabetes consultations during follow-up | T0 | T-4 | T-12 |
 | --- | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=2> Primary outcome |  |  |  |  |  |
 | Daily functioning | DFT | 1 |  | *

[Assistant]
| * | * |
 | <COLSPAN=2> Secondary outcomes |  |  |  |  |  |
 | Diabetes-related emotional distress | PAID | 20 |  | * | * | * |
 | <ROWSPAN=2> Mental health problems | PSYCHLOPS | 9 | *2 | *1 | * | * |
 | 4DSQ | 50 |  |  | * | * |
 | Quality of life | SF-12 | 12 |  | * | * | * |
 | Participation and autonomy | IPA | 32 + 9 |  | * | * | * |
 | Job performance | SF-HLQ | 5 |  | * | * | * |
 | Self-management knowledge and behaviour | PIH-NL | 12 |  | * | * | * |
 | General self-efficacy | GSES-12 | 12 |  | * | * | * |
 | Control over the disease | Average blood glucose level (HbA1c) | 1 | * |  |  |  |
 | Health care use |  | 5 |  | * | * | * |
 | <COLSPAN=2> Covariates |  |  |  |  |  |
 | <ROWSPAN=6> Patient demographics | Sex | 1 |  | * |  |  |
 | Age | 1 |  | * |  |  |
 | Year of diagnosis | 1 |  | * |  |  |
 | Treatment of diabetes | 1 |  | * |  |  |
 | Marital status | 1 |  | * |  |  |
 | Education | 1 |  | * |  |  |
 | <ROWSPAN=3> Practice nurse demographics | Age | 1 |  | * |  |  |
 | Training | 1 |  | * |  |  |
 | Type of general practice(s) (one GP, two GPs, group, health centre) | 1 |  | * |  |  | </md>


[User] <|image|>Convert the illustration into Markdown language.

[Assistant]
<md> |  | Torso | LU arm | LW arm | L Hand | RU arm | RW arm | R hand | Average |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | Hernández-Vela et al. [4] | 98.44 | 78.93 | 84.38 | 88.32 | 82.57 | 88.85 | 93.86 | 87.91 |
 | Liang et al. [10] | 94.10 | 93.57 | 90.43 | 87.31 | 93.13 | 87.84 | 85.79 | 90.31 |
 | RW | 92.29 | 85.06 | 95.71 | 96.69 | 85.65 | 95.46 | 95.75 | 92.37 |
 | Our method, no line | 96.13 | 87.46 | 95.66 | 96.02 | 88.59 | 95.45 | 95.53 | 93.55 |
 | Our method, with line | 98.65 | 87.67 | 92.84 | 95.92 | 91.40 | 91.47 | 95.48 | 93.35 | </md>


[User] <|image|>Convert the diagram to Markdown syntax.

[Assistant]
<md> | Subject | Chedoke | Sex | Age | Months Post Stroke | Affected Arm |
 | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=6> Keypad |
 | E1 | 6 | F | 53 | 36.2 | R |
 | E2 | 5 | M | 57 | 96.3 | R |
 | E3 | 5 | F | 51 | 6.6 | L |
 | E4 | 5 | M | 46 | 61.2 | L |
 | E5 | 5 | M | 56 | 12.6 | R |
 | E6 | 5 | M | 49 | 39.4 | L |
 | E7 | 5 | F | 69 | 74 | R |
 | Mean (SD) | 5.1 (0.4) | 57.1% Male | 54 (7) | 46.6 (32.5) | 42.9% left affected |
 | <COLSPAN=6> OT |
 | C1 | 5 | F | 58 | 89 | R |
 | C2 | 5 | M | 58 | 10.2 | L |
 | C3 | 5 | M | 70 | 14.2 | L |
 | C4 | 5 | F | 53 | 136.4 | L |
 | C5 | 5 | M | 56 | 15.4 | R |
 | C6 | 5 | M | 66 | 35.3 | L |
 | C7 | 5 | M | 55 | 35 | L |
 | Mean (SD) | 5.0 (0) | 71.4% Male | 59 (6) | 47.9 (47.4) | 71.4% left affected | </md>


[User] <|image|>Express the illustration as Markdown code.

[Assistant]
<md> |  | <COLSPAN=5> Month(s) |
 | --- | --- | --- | --- | --- | --- |
 |  | 0 | 3 | 6 | 9 | 12 |
 | Primary outcome |  |  |  |  |  |
 | Average overall knee pain severity over the previous week (0 to 10 NRS) | ✓ | ✓ | ✓ | ✓ | ✓ |
 | Secondary outcomes |  |  |  |  |  |
 | Imaging assessments: |  |  |  |  |  |
 | MRI of signal knee | ✓ |  | ✓ |  |  |
 | Clinical assessments: |  |  |  |  |  |
 | Knee examination | ✓ |  |  |  |  |
 | Self-reported questionnaires: |  |  |  |  |  |
 | WOMAC 3.1 (pain, stiffness and function) - five-point Likert scale | ✓ | ✓ | ✓ | ✓ | ✓ |
 | ICOAP | ✓ | ✓ | ✓ | ✓ | ✓ |
 | 11-point NRS for: | ✓ | ✓ | ✓ | ✓ | ✓ |
 | Worst knee pain severity,/ global disease activity and pain in other joints over the past week |  |  |  |  |  |
 | Satisfaction with knee function over the past 2 days |  |  |  |  |  |
 | Knee pain, aching or stiffness over the past month (no days to all days) |  |  |  |  |  |
 | Globala improvement in knee problem, pain and function |  | ✓ | ✓ | ✓ | ✓ |
 | Pain elsewhere (pain manikin) | ✓ | ✓ | ✓ | ✓ | ✓ |
 | Duration of knee pain over the past 12 months (<7 days, 1 to 4 weeks, >1 month, <3 months or >3 months) | ✓ |  |  |  |  |
 | Onset of knee pain (last 12 months, 1 to 5 years, 5 to 10 years or 10 years or more) | ✓ |  |  |  |  |
 | Quality of life: SF-12 v2 and OAQoL [40] | ✓ |  | ✓ |  | ✓ |
 | EuroQol EQ-5D [41,42] | ✓ |  | ✓ |  | ✓ |
 | Depression and anxiety: HADS | ✓ |  | ✓ |  | ✓ |
 | Resource use: | ✓ |  | ✓ |  | ✓ |
 | Demographics and medical history | ✓ |  |  |  |  |
 | Brief medication questionnaire |  | ✓ | ✓ | ✓ | ✓ |
 | Concomitant medicationb | ✓ | ✓ | ✓ | ✓ | ✓ |
 | Adverse eventsb |  | ✓ | ✓ | ✓ | ✓ | </md>


[User] <|image|>Interpret the illustration as Markdown format.

[Assistant]
<md> | Clinical trial | Patient population | Restrictive strategy (Hb trigger – target) (g/dl) | Liberal strategy (Hb trigger – target) (g/dl) | Reduction in blood utilization | <COLSPAN=4> Primary outcome |
 |  |  |  |  |  | Event | Restrictive strategy incidence (%) | Liberal strategy incidence (%) | Pvalue |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | Hébert and colleagues [3] (n = 838) | Critically ill (adults) | 7 to 8.5 | 10 to 10.7 | 54% less RBC units transfused | 30-day mortality | 18.7 | 23.3% | 0.11 |
 | Hajjar and colleagues [5] (n = 502) | Cardiac surgery (adults) | 8 to 9.1 | 10 to 10.5 | 58% less RBC units transfused | Composite endpoint | 11 | 105 | 0.85 |
 |  |  |  |  |  | • 30-day mortality | 6 | 6 | 0.93 |
 |  |  |  |  |  | • Cardiogenic shock | 9 | 1 | 0.42 |
 |  |  |  |  |  | • ARDS | 2 | 5 | 0.99 |
 |  |  |  |  |  | • Acute renal injury requiring dialysis | 4 |  | 0.99 |
 | Carson and colleagues [7] (n = 2,016) | Femur fracture (older adults) | 8.0 to 9.5 | 10.0 to 11.0 | 65% less RBC units transfused | Composite endpoint | 34.7 | 35.2 | NS |
 |  |  |  |  |  | • 60-day mortality | 28.1 | 27.6 | NS |
 |  |  |  |  |  | • 60-day inability to walk | 6.6 | 7.6 | NS |
 | Villanueva and colleagues [9] (n = 921) | Gastrointestinal bleeding (adults) | 7 to 9.2 | 9 to 10.1 | 59% less RBC units transfused | 45-day all-cause mortality | 5 | 9 | 0.02 |
 | Holst and colleagues (n = 998) [8] | Sepsis in the ICU (adults) | <7.0 | 7.0 to 9.0 | 50% less RBC units transfused | 90-day all-cause mortality | 43 | 45 | 0.44 | </md>


[User] <|image|>Convert the image into Markdown format.

[Assistant]
<md> | High Risk BCC |
 | --- |
 | Aggressive histological subtype; morphoeic, micronodular |
 | Large size >2 cm |
 | Perineural, perivascular invasion |
 | Central facial site; periocular, nasal, perioral |
 | Recurrent BCC | </md>


[User] <|image|>Transcribe the image into Markdown format.

[Assistant]
<md> | Species | LONG | MTR | ST | FT | ED | MD | VP | MVP | HA |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | Pinus koraiensis | 300 | 40 | 4 | 4 | 50 | 100 | 0 | 0 | 120 |
 | Picea koraiensis | 300 | 30 | 4 | 4 | 50 | 150 | 0 | 0 | 120 |
 | Tilia amurensis | 300 | 30 | 4 | 2 | 100 | 100 | 0.1 | 60 | 80 |
 | Acer mono | 200 | 30 | 4 | 3 | 100 | 200 | 0.3 | 60 | 80 |
 | Populus davidiana | 150 | 30 | 2 | 1 | -1 | -1 | 1 | 0 | 40 |
 | Betula platyphylla | 150 | 20 | 1 | 1 | 20 | 4000 | 0.8 | 50 | 60 |
 | Ulmus pumila | 250 | 30 | 3 | 3 | 300 | 1000 | 0.7 | 60 | 60 |
 | Juglans mandshurica | 250 | 30 | 2 | 4 | 50 | 100 | 0.9 | 60 | 80 |
 | Fraxinus mandshurica | 300 | 30 | 4 | 2 | 50 | 150 | 0.1 | 80 | 80 |
 | Quercus mongolica | 300 | 30 | 4 | 3 | 40 | 100 | 0.5 | 60 | 80 | </md>


[User]
<|image|>Continue parse the picture with markdown style: <md> |  | <COLSPAN=3> EEG abnormality scores |
 | Score | 0 | 1 | <COLSPAN=2> 2 |
 | --- | --- | --- | --- |
 | Delta | Absent

[Assistant]
| Present |  |
 | Theta | Absent | Present | Higher, sharp or saw-tooth |
 | IED | Absent | Brief Spikes | Spike and wave |
 |  |  | EEG laterality score |
 | Left = 1 | Left > Right = 2 | Left ≈ Right = 3 | Left < Right = 4 | Right = 5 | </md>


[User]
<|image|>Parse the illustration content behind with markdown code: <md> | Question |
 | --- |
 | The formative OSCE helped me to prepare for the summative OSCE |
 |

[Assistant]
I felt confident going into the summative OSCE |
 | I was less anxious going into the summative OSCE because of my experience of the formative OSCE |
 | I think I have done better in the summative OSCE compared to the formative OSCE | </md>


[User] <|image|>Express the illustration as Markdown code.

[Assistant]
<md> | Gene model | Absolute expression value in primary root at V1 |
 | --- | --- |
 | GRMZM2G153722 | 7456.31 |
 | GRMZM2G053511 | 66.76 |
 | GRMZM2G002879 | 1216.56 |
 | GRMZM2G154864 | 4826.04 |
 | GRMZM2G070837 | 53.19 |
 | GRMZM2G095969 | 70.27 |
 | GRMZM2G322186 | 4784.54 | </md>


[User] <|image|>Parse the photo content behind with markdown code: <md> |  | <COLSPAN=2> BrAC Pre-Drive 2 (%) | <COLSPAN=2> BrAC Post-Drive 2

[Assistant]
(%) |
 |  | AS | CHO | AS | CHO |
 | --- | --- | --- | --- | --- |
 | Males | 0.036 ± 0.010 | 0.025 ± 0.007 | 0.028 ± 0.008 | 0.022 ± 0.006 |
 | Females | 0.024 ± 0.009 | 0.017 ± 0.008 | 0.018 ± 0.006 | 0.010 ± 0.008 | </md>


[User] <|image|>Convert the image into Markdown format.

[Assistant]
<md> | Best model* | Training balanced accuracy | Testing balanced accuracy | Cross-validationconsistency | Sign test (P) |
 | --- | --- | --- | --- | --- |
 | 1 | 0.397 | 0.612 | 6/10 | 8 (0.423) |
 | 1, 2 | 0.525 | 0.605 | 9/10 | 8 (0.342) |
 | 1, 2, 3 | 0.687 | 0.672 | 10/10 | 9 (0.015) |
 | 1, 2, 3, 4 | 0.585 | 0.612 | 7/10 | 7 (0.325) |
 | 1, 2, 3, 4, 5 | 0.575 | 0.512 | 8/10 | 6 (0.642) |
 | 1, 2, 3, 4, 5, 6 | 0.622 | 0.479 | 7/10 | 8 (0.576) |
 | 1, 2, 3, 4, 5, 6, 7 | 0.499 | 0.526 | 8/10 | 5 (0.734) |
 | 1, 2, 3, 4, 5, 6, 7, 8 | 0.613 | 0.611 | 7/10 | 6 (0.412) |
 | 1, 2, 3, 4, 5, 6, 7, 8, 9 | 0.598 | 0.572 | 6/10 | 7 (0.665) |
 | 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 | 0.613 | 0.476 | 8/10 | 5 (0.684) |
 | 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 | 0.504 | 0.644 | 9/10 | 6 (0.337) | </md>


[User] <|image|>Translate the illustration into Markdown format.

[Assistant]
<md> |  | <COLSPAN=5> Total phenolic content [mg/L] |
 |  | o/n | 1 h | 2 h | 4 h | 6 h |
 | --- | --- | --- | --- | --- | --- |
 | Average | 1,559 ± 167 | 1,575 ± 165 | 1,621 ± 139 | 1,676 ± 168 | 1,706 ± 167 |
 | Min | 1.025 | 1.121 | 979 | 1.188 | 1.145 |
 | Max | 1.749 | 1.66 | 1.698 | 1.853 | 1.779 |
 |  | <COLSPAN=5> Reversed phase chromatography [mg/L] |
 |  | o/n | 1 h | 2 h | 4 h | 6 h |
 | Average | 6 ± 5 | 4 ± 3 | 4 ± 3 | 4 ± 4 | 7 ± 5 |
 | Min | 0 | 0 | 0 | 0 | 0 |
 | Max | 21 | 12 | 12 | 14 | 15 | </md>


[User]
<|image|>Parse the following content of the diagram in markdown code: <md> | <COLSPAN=2>  | Beliefs in effectiveness | Beliefs in safety production | Perceived norms | Self-efficacy | Limitations of the double-check |
 | --- | --- | --- | --- | --- | --- | --- |
 | <ROWSPAN=2> Primary place of work | On ward | 5.7 [0.8] | 5.3 [0.7] | 5.0 [1.0]** | 5.9 [0.6] | 3.3 [0.9] |
 | Ambulatory infusion unit | 5.8 [0.7] | 5.2 [0.9] | 5.5 [1.1]** | 5.9 [0.7] | 3.1 [1.2] |
 | <ROWSPAN=2> Years of practice in oncology | ≤ 5 years | 5.7 [0.8] | 5.3 [0.8] | 5.0 [1.0] | 5.8 [0.7] | 3.2 [1.0] |
 | >5 years | 5.7 [0.8] | 5.3 [0.8] | 5.2 [1.0] | 5.9 [0.6] | 3.3 [1.0] |
 | <ROWSPAN=2> Weekly hours in direct patient care | ≤ 40 h | 5.7 [0.8] | 5.3 [0.8] | 5.1 [1.0] | 5.8 [0.6]* | 3.3 [1.0] |
 | >40 h | 5.7 [0.8] | 5.3 [0.8] | 5.1 [1.0] | 6.0 [0.5]* | 3.3 [1.1] |
 | <ROWSPAN=2> Qualification |

[Assistant]
Nurse | 5.8 [0.7] | 5.3 [0.8] | 5.1 [1.0] | 5.9 [0.6] | 3.4 [1.0] |
 | Nursing expert/head nurse | 5.6 [1.0] | 5.2 [0.8] | 5.1 [1.1] | 5.9 [0.6] | 3.2 [1.0] | </md>


[User]
<|image|>Continue parse the picture with markdown style: <md> | <ROWSPAN=2> Variable | <COLSPAN=3> Univariate analysis |  | <COLSPAN=3> Multivariate analysis |
 | OR | p | 95%CI |  | OR | p | 95%CI |
 | --- | --- | --- | --- | --- |

[Assistant]
--- | --- | --- |
 | Triglycerides (TG) | (TG) | 0.006 | 1.001-1.008 |  | 1.004 | 0.018 | 1.001-1.008 |
 | Mean platelet volume (MPV) | 1.271 | 0.003 | 1.084-1.490 |  | 1.215 | 0.021 | 1.030-1.434 |
 | Neutrophil count | 1.159 | 0.007 | 1.040-1.292 |  |  |  |  |
 | White cell (WBC) count | 1.142 | 0.022 | 1.020-1.278 |  | 1.142 | 0.020 | 1.021-1.278 | </md>


[User] <|image|>Transform the photo into Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Psychiatric Comorbidities | <COLSPAN=2> Diagnostic codes (N = 196) | <COLSPAN=2> NLP (N = 486) | <COLSPAN=2> Reference group (N = 17,183) |
 | n | % | n | % | n | % |
 | --- | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=7> Psychiatric Comorbidities |
 | Depression | 171 | 87.24 | 353 | 72.63 | 5150 | 29.97 |
 | Schizophrenia | 10 | 5.10 | 10 | 2.06 | 95 | 0.55 |
 | Bipolar | 45 | 22.96 | 40 | 8.23 | 489 | 2.85 |
 | PTSD | 58 | 29.59 | 76 | 15.64 | 590 | 3.43 |
 | Substance abuse | 102 | 52.04 | 173 | 35.60 | 2332 | 13.57 |
 | Anxiety | 100 | 51.02 | 259 | 53.29 | 5184 | 30.17 |
 | <COLSPAN=7> Psychiatric comorbidities at encounters to Department Psychiatry/Mental Health/Behavioral Health (ever) |
 | Depression | 93 | 47.45 | 180 | 37.04 | 1536 | 8.94 |
 | Schizophrenia | 7 | 3.57 | 4 | 0.82 | 43 | 0.25 |
 | Bipolar | 18 | 9.18 | 26 | 5.35 | 234 | 1.36 |
 | PTSD | 29 | 14.80 | 44 | 9.05 | 312 | 1.82 |
 | Substance abuse | 43 | 21.94 | 36 | 7.41 | 177 | 1.03 |
 | Anxiety | 30 | 15.31 | 113 | 23.25 | 1058 | 6.16 |
 | <COLSPAN=7> Psychiatric comorbidities at encounters to Emergency Department (Ever) |
 | Depression | 128 | 65.31 | 80 | 16.46 | 608 | 3.54 |
 | Schizophrenia | 6 | 3.06 | 2 | 0.41 | 22 | 0.13 |
 | Bipolar | 25 | 12.76 | 8 | 1.65 | 76 | 0.44 |
 | PTSD | 28 | 14.29 | 9 | 1.85 | 54 | 0.31 |
 | Substance abuse | 74 | 37.76 | 57 | 11.73 | 652 | 3.79 |
 | Anxiety | 51 | 26.02 | 42 | 8.64 | 660 | 3.84 | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> |  | <COLSPAN=2> Body image perception, n (%) | <ROWSPAN=2> Adjusteda OR (95 % CI) | <ROWSPAN=2> P-value |
 |  | Correct | Underestimated |
 | --- | --- | --- | --- | --- |
 | Exercise |  |  |  |  |
 | Daily | 343 (60.0) | 63 (65.6) | 1.28 (0.76–2.16) | 0.346 |
 | Sometimes | 68 (11.9) | 10 (10.4) | 1.05 (0.47–2.35) | 0.903 |
 | Never | 161 (28.1) | 23 (24.0) | 1.00 |  |
 | Snacking after dinner |  |  |  |  |
 | Yes | 276 (47.8) | 56 (57.1) | 1.44 (0.93–2.23) | 0.100 |
 | No | 302 (52.2) | 42 (42.9) | 1.00 |  |
 | Skipping breakfast |  |  |  |  |
 | No | 548 (93.4) | 91 (91.9) | 1.00 |  |
 | Yes | 39 (6.6) | 8 (8.1) | 1.33 (0.60–2.98) | 0.485 |
 | Wakeup time |  |  |  |  |
 | Before 6:30 | 318 (55.8) | 45 (46.4) | 1.00 |  |
 | 6:30–6:59 | 90 (15.8) | 17 (17.5) | 1.36 (0.74–2.51) | 0.329 |
 | After 7:00 | 162 (28.4) | 35 (36.1) | 1.62 (1.00–2.64) |

[Assistant]
0.052 |
 | Bedtime |  |  |  |  |
 | Before 22:00 | 36 (6.7) | 9 (9.5) | 1.00 |  |
 | 22:00–22:59 | 262 (48.4) | 46 (48.4) | 0.73 (0.33–1.63) | 0.445 |
 | After 23:00 | 243 (44.9) | 40 (42.1) | 0.72 (0.32–1.63) | 0.435 |
 | Hours of sleep |  |  |  |  |
 | < 8 | 176 (32.8) | 22 (23.4) | 1.00 |  |
 | 8–9 | 288 (53.7) | 54 (57.4) | 1.44 (0.85–2.46) | 0.179 |
 | 9+ | 72 (13.4) | 18 (19.1) | 1.85 (0.93–3.67) | 0.081 | </md>


[User]
<|image|>Continue parse the table with markdown style: <md> |  | <COLSPAN=4> CONTROL | <COLSPAN=4> STROKE |
 |  | <COLSPAN=2> Thumb | <COLSPAN=2> Long Fingers | <COLSPAN=2> Thumb | <COLSPAN=2> Long Fingers |
 |  | MCPJ | IPJ | MCPJ | IPJ | MCPJ | IPJ | MCPJ | IPJ |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | ROM [deg] | 61.1(23.8) | 64.0(24.4) | 90.3(12.7) | 109.1(12.5) | 25.8***(18.4) | 40.5**(20.0) | 50.4***(20.4) | 64.5***(27.7) |
 |  |  |  | <COLSPAN=2> §§§ | <COLSPAN=2> §§ | <COLSPAN=2> § |
 | Max. ext. angle [deg] | 143.0(14.6) | 188.8(16.8) | 186.7(8.1) | 189.5(8.7) | 116.6***(22.6) | 180.4(18.2) | 166.7***(17.0) | 159.5***(26.8) |
 |  | <COLSPAN=2> §§§ |  |  | <COLSPAN=2> §§§ |  |  |
 | Max. Flex. Angle [deg] | 81.7(16.4) | 125.2(20.5) | 96.6(11.2) | 80.4(7.7) | 90.7(17.5) | 139.6*(18.8) | 116.3***(13.1) | 95.0***(12.8) |
 |  | <COLSPAN=2> §§§ | <COLSPAN=2> §§§ |

[Assistant]
<COLSPAN=2> §§§ | <COLSPAN=2> §§ |
 | Vpk - Hand Opening [deg/s] | 191.5(98.8) | 272.8(146.5) | 354.2(181.1) | 490.4(228.4) | 22.7***(23.6) | 16.5***(23.5) | 34.6***(20.8) | 40.7***(30.9) |
 |  | <COLSPAN=2> §§ | <COLSPAN=2> §§§ |  |  |  |  |
 | Vpk - Hand Closing [deg/s] | 184.1(109.4) | 189.3(103.4) | 279.2(146.7) | 437.7(172.5) | 50.4***(48.9) | 41.5***(35.4) | 51.7***(31.8) | 83.5***(55.1) |
 |  |  |  | <COLSPAN=2> §§§ |  |  | <COLSPAN=2> §§ | </md>


[User]
<|image|>Continue parse the diagram with markdown style: <md> | Variable | Subject with fallsn = 178 | Subject without fallsn = 850 | Crude OR(95%CI) | Adjusted OR(95%CI) |
 | --- | --- | --- | --- | --- |
 | <COLSPAN=5> Gender n(%) |
 | Men | 82 (14.3) | 491 (85.7) | 1 | 1.15(0.74–1.79) |
 | Women | 96 (21.1) | 359 (78.9) | 1.6(1.16–2.22) | 1 |
 | <COLSPAN=5> aBMI(kg/m2) |
 | > 30 | 62 (18.7) | 270 (81.3) | 1 | 1 |
 | 25–30 | 74 (17.2) | 357 (82.8) | 1.11(076–1.6) | 1.09(0.68–1.7)

[Assistant]
|
 | < 30 | 42 (15.8) | 223 (82.4) | 0.82(053–1.26) | 1.1(0.71–0.69) |
 | <COLSPAN=5> bOsteoporosis n(%) |
 | Absent | 95 (14.2) | 574 (85.8) | 1 | 1 |
 | Present | 83 (23.1) | 276 (76.9) | 1.88(1.34–3.52) | 1.38(0.78–1.9) |
 | <COLSPAN=5> cQMS (kg) |
 | > 30 | 23 (9.3) | 225 (90.7) | 1 | 1 |
 | 15–30 | 97 (18.2) | 430 (81.8) | 2.18(1.34–3.52) | 1.72(1.01–2.9) |
 | < 15 | 58 (23.5) | 189 (76.5) | 3.01(1.78–5) | 2.02(1.06–3.85) | </md>


[User] <|image|>Interpret the figure as Markdown format.

[Assistant]
<md> | <ROWSPAN=3> Predicted malarial status | <COLSPAN=8> True clinical diagnosis of malaria |
 | <COLSPAN=2> 5–9 Years | <COLSPAN=2> 10–17 Years | <COLSPAN=2> 18 Years and above | <COLSPAN=2> Total |
 | Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=9> (a) Predictive dataset: Kalisizo Hospital |
 | Positive | 6 | 4 | 10 | 3 | 65 | 8 | 81 | 15 |
 | Negative | 5 | 4 | 4 | 3 | 25 | 14 | 34 | 21 |
 | Total | 11 | 8 | 14 | 6 | 90 | 22 | 115 | 36 |
 | <COLSPAN=9> (b) Training dataset: Kisubi Hospital |
 | Positive | 56 | 22 | 20 | 19 | 11 | 15 | 90 | 16 |
 | Negative | 5 | 270 | 5 | 105 | 4 | 290 | 11 | 705 |
 | Total | 61 | 292 | 25 | 124 | 15 | 305 | 101 | 721 | </md>


[User]
<|image|>What are the following photo content in markdown style: <md> |  | White Mean (SD) N | Non-White Mean (SD) N | Significance | Effect size |
 | --- | --- | --- | --- | --- |
 | Total number of points achieved at A level | 17.71 (9.17) N = 2376 | 16.42 (9.15) N = 355 | t = 2.474 p = .013 | -.141 |
 |  | White N (%) | Non-White N(%) |  | Odds Ratio (95% CI) |
 | Taking one or more A-levels (excluding General Studies) | 4666/11273 = 41.4% | 738/1777 = 41.5% | χ2 = .012 (1) p = .911 | OR = 1.01 (.91–1.11) d = .005 |

[Assistant]
| Taking one or more science A-levels | 2701/11273 = 24.0% | 515/1777 = 29.0% | χ2 = 20.84 (1) p < .001 | 1.30 (1.16–1.45) d = .145 |
 | Taking A-level Chemistry | 744/11273 = 6.6% | 202/1776 = 11.4% | χ2 = 51.98 (1) p < .001 | 1.82 (1.54–2.14) d = .331 | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> |  | <COLSPAN=2> High glucoraphanin broccoli | <COLSPAN=2> Standard broccoli |
 |  | Male (n = “28) | Female (n = 19) | Male (n = 27) | Female (n = 21) |
 | --- | --- | --- | --- | --- |
 | Age (y) | 60.2

[Assistant]
± 6.38a) | 63.0 ± 5.72 | 59.8 ± 5.49 | 63.5 ± 7.09 |
 | BMI (kg/m2) | 26.7 ± 3.43 | 26.0 ± 4.70 | 27.5 ± 3.67 | 26.3 ± 4.20 |
 | Systolic BP (mmHg) | 128.1 ± 14.80 | 128.4 ± 12.9 | 126.3 ± 11.24 | 134.1 ± 10.84 |
 | Diastolic BP (mmHg) | 83.1 ± 9.87 | 76.9 ± 10.20 | 81.6 ± 7.51 | 78.9 ± 6.10 |
 | Weight (kg) | 83.4 ± 13.06 | 68.9 ± 10.14 | 86.5 ± 12.35 | 68.0± 12.25 |
 | Waist circumference (cm) | 98.7 ± 11.20 | 87.6 ± 11.73 | 100.5 ± 8.66 | 87.2 ± 11.50 |
 | Hip circumference (cm) | 105.5 ± 6.25 | 107.0± 8.66 | 106.8 ± 6.95 | 105.3 ± 10.17 |
 | Total cholesterol (mmol/L) | 5.9 ± 0.86 | 6.7 ± 0.71 | 5.8 ± 0.96 | 6.7 ± 0.90 |
 | LDL cholesterol (mmol/L) | 4.2 ± 0.71 | 4.6 ± 0.77 | 4.1 ± 0.79 | 4.7 ± 0.80 |
 | HDL cholesterol (mmol/L) | 1.4 ± 0.28 | 1.8 ± 0.32 | 1.4 ± 0.31 | 1.7 ± 0.29 |
 | Triglycerides (mmol/L) | 1.6 ± 0.69 | 1.1 ± 0.32 | 1.5±0.57 | 1.2 ± 0.30 |
 | Glucose (mmol/L) | 5.7 ± 0.47 | 5.7 ± 0.46 | 5.7 ± 0.43 | 5.7 ± 0.48 |
 | JBS2 CVD risk score (%) | 17.5 ± 5.85 | 14.4 ± 4.89 | 17.1 ± 5.54 | 12.5 ± 2.52 | </md>


[User]
<|image|>Parse the image content behind with markdown code: <md> | IRD patient numbers | Patient origin (predominant) | NGS technology | Pathogenic/likely pathogenic mutations (%) | Reference |
 | --- | --- | --- | --- | --- |
 | 100 | Dutch | Target capture 111 genes | ∼ 50% | Neveling et al. 2012 (10) |
 | 20 | France | Target capture 254 genes | 57% | Audo et al. 2012 (11) |
 | 50 | UK | Target capture 105 genes | 50-50% | O’Sullivan et al. 2012 (12) |
 | 50 | UK | Target capture 73 genes | 53% (early onset IRD;25% overall) | Shanks et al. 2013 (13)

[Assistant]
|
 | 192 | US | Target capture (GEDi) 214 genes | 51% | Consugar et al. 2015 (14) |
 | 105 | eyeGENE® database | Target capture 195 genes | 49.5% | Ge et al. 2015 (15) |
 | 82 | N Ireland | Target capture 186 genes | 60% | Zhao et al. 2015 (16) |
 | 88 | Italy | Target capture 72 genes | 59.1% | Bernardis et al. 2016 (17) |
 | 309 | Ireland | Target capture 216 genes | 57% | Carrigan et al. 2016 (18) |
 | 537 | Worldwide | Target capture 105 genes | 51% | Ellingford et al. 2016 (19) |
 | 47 | Spain | Target capture 75 genes | 57.4% | Perez-Carro et al. 2016 (20) |
 | 88 | European | Target capture & WES | 61% | Weisschuh et al. 2016 (21) |
 | 58 | Swiss | WES | 64% | Tiwari et al. 2016 (22) |
 | 33 | Mixed | WES | 55% | de Castro-Miró et al. 2016 (23) |
 | 59 | Spain | WES | 71.8% | Riera et al. 2017 (24) |
 | 266 | Dutch | Target panel & WES | 52% | Haer-Wigman et al. 2017 (25) | </md>


[User] <|image|>Convert the illustration into Markdown language.

[Assistant]
<md> | Model | p | l | Parameters estimates | Positively selected sites |
 | --- | --- | --- | --- | --- |
 | M0: one-ratio | 1 | -5974.07 | ω = 0.0621 | None |
 | <underline>Branch-site model</underline>: |  |  |  |  |
 | Model A | 3 | -5925.68 | p0 = 0.503, p1 = 0.102(p2 + p3) = 0.393ω2 = 14.201 | Sites for foreground lineage: 17M 19T 22Q 29C 51W 63T 70G 71D 74L 75Q 76L 103G 126A 163S 209G 226V 248T 257A (at P > 0.95) | </md>


[User] <|image|>Express the illustration as Markdown code.

[Assistant]
<md> | <ROWSPAN=2>  | <COLSPAN=2> Quadriceps | <COLSPAN=2> Hamstrings | <COLSPAN=2> Adductor | <COLSPAN=2> Whole thigh |
 | Young | Old | Young | Old | Young | Old | Young | Old |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | IMF | 64.4 (32.1) | 66.5 (15.0) | 41.1 (24.4) | 51.7 (13.4) | 55.8 (39.2) | 46.7 (16.3) | 161.3 (93.1) | 164.9 (39.4) |
 | Skeletal muscle | 1304.2 (373.2) | 824.3 (247.2)* | 438.5 (132.3) | 316.7 (80.5)* | 655.2 (226.4) | 475.8 (161.1)* | 2397.9 (712.1) | 1616.8 (469.0)* |
 | Normalized IMF | 1.0 (0.4) | 1.2 (0.2) | 0.6 (0.3) | 0.9 (0.2)* | 0.9 (0.5) | 0.8 (0.3) | 2.5 (1.1) | 2.9 (0.6) |
 | Normalized skeletal muscle | 20.7 (3.8) | 14.4 (2.8)* | 7.0 (1.5) | 5.6 (1.1)* | 10.4 (2.7) | 8.2 (1.9)* | 38.1 (7.6) | 28.2 (5.2)* |
 | Volume-based IMF content | 4.8 (2.2) | 7.8 (2.4)* | 8.6 (4.7) | 14.4 (3.7)* | 8.3 (5.4) | 9.5 (3.7) | 6.5 (3.3) | 9.7 (2.9)* | </md>


[User] <|image|>Transcribe the illustration into Markdown format.

[Assistant]
<md> | Study | Mutation(s) | Aβ42 | Tau | pTau | Comments |
 | --- | --- | --- | --- | --- | --- |
 | Moonis et al. (69)6 MC6 Unrelated controls | PSEN-1 C410Y, PSEN-1 P242H, and R352H | ↓ | N.S. | Not tested | MC EYO −8 ± 3 |
 | Ringman et al. (74)20 MC9 NC | PSEN-1 A431E, PSEN-1 L235V, PSEN-1 G206A, APP V717I | ↓ (trend) | ↑ | ↑ | MC EYO ~−12NC EYO −9 ± 12 |
 | Fortea et al. (70)8 MC5 NC | PSEN-1 L286P, PSEN-1 M139T | ↓ (trend) | N.S. | N.S. | MC EYO −6 ± 10NC EYO −7 ± 9 |
 | Scholl et al. (71)4 MC7 Unrelated controls | APP KM670/671 NL, APP E693G, PSEN-1 H163Y | ↓ | ↑ | ↑ |  |
 | Reiman et al. (72)10 MC10 NC | PSEN-1 E280A (API) | ↑ | N.S. | N.S. | MC EYO ~−25NC EYO ~−26 |
 | Ringman et al. (75)13 MC5 NC | PSEN-1 A431E, PSEN-1 L235V, PSEN-1 S212Y, APP V717I | ↓ | ↑ | ↑ | MC EYO −12 ± 10NC EYO −6 ± 14 |
 | Bateman et al. (11)88 MC40 NC | Many (DIAN) | ↓ at EYO −10 and closer to EAO | ↑ at EYO −15 and closer to EAO | Not shown |  |
 | Thordardottir et al. (76)10 MC12 NC | APP KM670/671 NL, APP E693G, PSEN-1 H163Y, PSEN-1 I143T | ↓ | ↑ | ↑ | MC EYO −7 ± 9NC EYO −7 ± 12 |
 | Fleisher et al. (12)32 MC22 NC | PSEN-1 E280A (API) | ↓ at EYO −25 and closer to EAO | ↑ at EYO −20 and closer to EAO | ↑ at EYO −18 and closer to EAO |  | </md>


[User]
<|image|>Parse the following content of the photo in markdown code: <md> | <ROWSPAN=2> Cross | <ROWSPAN=2> Chr. | <ROWSPAN=2> LOD | <ROWSPAN=2> PVE | <ROWSPAN=2> Peak marker | <COLSPAN=3> Phenotype mean +/- standard error |
 | MM | MF | FF |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | PAXB | 4 | 8.9 | 12.5 | Chr4_152 | 11.54 +/-

[Assistant]
0.08 | 11.2 +/- 0.05 | 10.97 +/- 0.06 |
 | FTC | 4 | 20.7 | 20.7 | Chr4_152 | 11.21 +/- 0.07 | 10.83 +/- 0.04 | 10.4 +/- 0.06 |
 | BEPA | 4 | 11.2 | 9.5 | Chr4_131 | 11.58 +/- 0.07 | 11.26 +/- 0.04 | 11.08 +/- 0.06 |
 | PAXB | 20 | 7.9 | 11.5 | Stn216 | 11.54 +/- 0.07 | 11.25 +/- 0.05 | 10.99 +/- 0.07 |
 | FTC | 20 | 10.2 | 9.7 | Stn212 | 11.04 +/- 0.06 | 10.85 +/- 0.04 | 10.54 +/- 0.06 |
 | BEPA | 20 | 24.8 | 22.4 | Stn216 | 11.65 +/- 0.06 | 11.31 +/- 0.04 | 10.8 +/- 0.05 | </md>


[User]
<|image|>Continue parse the table with markdown style: <md> |  | <COLSPAN=3> Males (n = 403) | <COLSPAN=3> Females (n = 225) | <COLSPAN=2> Both genders (n = 628) |
 |  | SDICH(n = 177) | Controls(n = 226) | P-Value | SDICH(n = 83) | Controls(n = 142) | P-Value | SDICH(n = 260) | P-Value |
 | ---

[Assistant]
| --- | --- | --- | --- | --- | --- | --- | --- |
 | Age (years) | 58.3 ± 1.0 | 58.7 ± 0.9 | 0.82 | 65.1 ± 1.3 | 62.6 ± 0.9 | 0.05 |  | 0.61 |
 | Hypertension (%) | 91.5 | 32.3 | <0.0001 | 95.2 | 38.7 | <0.0001 |  | <0.0001 |
 | Diabetes mellitus (%) | 12.4 | 15.9 | 0.35 | 30.1 | 13.4 | 0.004 |  | 0.32 |
 | Alcohol use (%) | 46.9 | 19.5 | <0.0001 | 4.8 | 0 | 0.018 |  | <0.0001 |
 | Body mass index (kg/m2) | 25.2 ± 0.3 | 25.8 ± 0.3 | 0.13 | 24.4 ± 0.4 | 25.1 ± 0.4 | 0.31 |  | 0.08 |
 | Total cholesterol (mg/dL) | 176.9 ± 2.7 | 191.7 ± 3.0 | 0.0003 | 188.3 ± 4.1 | 204.6 ± 3.7 | 0.003 |  | <0.0001 |
 | Triglyceride (mg/dL) | 137.9 ± 6.1 | 143.7 ± 6.9 | 0.90 | 143.8 ± 8.3 | 147.3 ± 8.0 | 0.80 |  | 0.77 |
 | SDICH at supratentorium | 149 (84.2%) |  |  | 80 (96.4%) |  |  | 229 (88.1%) | 0.005a |
 | Hemorrhage size (cm3)b | 18.0 ± 1.6 |  |  | 13.1 ±1.6 |  |  | 16.3 ±1.2 | 0.03a |
 | modified Rankin scale > 3 | 49.1% |  |  | 52.5% |  |  | 50.2% | 0.62a | </md>


[User]
<|image|>Continue parse the image with markdown style: <md> | INH Induced method | Control (Mean ± SEM) (Min) | Standard (Mean ± SEM) (Min) | Test (Mean ± SEM) (Min) | Significance |
 | --- | --- | --- | --- | --- |
 | Time

[Assistant] for onset of convulsions | 28 ± 1.195 | 58.17 ± 6.676 | 135.0 ± 25.10 | (P<0.05) significant | </md>


[User] <|image|>Convert the figure into Markdown language.

[Assistant]
<md> |  | <COLSPAN=2> N (%)* | <COLSPAN=2> Crude results (n = 61,129) | <COLSPAN=2> Adjusted results** (n = 47,817) |
 | LAN exposure | Cases | Referents | Odds ratios | 95% CI | Odds ratios | 95% CI |
 | --- | --- | --- | --- | --- | --- | --- |
 | Low | 27,121 (63) | 10,970 (60) | <COLSPAN=2> Ref. | <COLSPAN=2> Ref. |
 | Medium | 5,974 (14) | 2,623 (14) | 1.13 | (1.07-1.19) | 1.06 | (0.97-1.16) |
 | High | 9,659 (23) | 4,782 (26) | 1.22 | (1.18-1.28) | 1.12 | (1.04-1.20)† | </md>


[User] <|image|>Convert the diagram to Markdown syntax.

[Assistant]
<md> | <COLSPAN=5> pg/mL | μM |
 |  | IL-4 | IL-10 | IL-12 | IFN-γ | NO |
 | --- | --- | --- | --- | --- | --- |
 | Con A | 226.84 ± 9.53 | 338.10 ± 11.49 | 26.85 ± 11.94 | 939.48 ± 0.00 | ND |
 | PLA | 33.67 ± 4.82 | 68.57 ± 6,88 | ND | 87.06 ± 12,23 | 1.39 ± 0.96 |
 | P2 | ND | ND | 18.37 ± 11.58 | ND | ND |
 | P3 | ND | ND | 16.44 ± 3.25 | ND | ND |
 | P8 | ND | 27.46 ± 0.74 | ND | ND | ND |
 | P9 | ND | 21.03 ± 0.16 | 8.02 ± 3.85 | ND | ND | </md>